Skip to main content

Talk Bio

Actionable Insights Powered by AI

Search This Blog

About

Posts

Wave aims for monthly dosing with RNA editing treatment for AATD now targets a monthly injection schedule for its WVE‑006 program in AATD.

on May 20, 2026

alpha 1-Antitrypsin Deficiency dosing monthly RNA Editing Wave Life Sciences

+

Wave Life Sciences is advancing an investigational RNA editing therapy, WVE-006, for alpha‑1 antitrypsin deficiency (AATD) with the goal of enabling monthly subcutaneous dosing. Sources: WVE-006 (GalNAc-RNA Editing) Achieves MZ-Like Phenotype ... Sanofi, Wave post updates in race to end AATD's 40-year drought Wave Life Sciences' RNA Editing Therapy Shows Promising R... RNA editing for the treatment of alpha-1 antitrypsin deficiency - PMC RNA Editing Therapy Shows Positive Proof-of-Mechanism Results ... Wave Crashes Despite Successful RNA Editing in AATD Study RNA Single-base Editing Therapy that Treats Genetic Lung and ... Wave Life Sciences Announces Data From 200 Mg Single ... Study Details | NCT06405633 | A Phase 1b/2a, Open-label Single ... Wave shares sink on new study results for RNA editing drug New Data - March 26,2026 Reimagining RNA medicine [PDF] RNA Editing for the Treatment of Alpha-1 Antitrypsin Deficiency ... Wave Life Sciences Annou...

Get link
Facebook
X
Pinterest
Email
Other Apps

TrumpRx adds more than 600 generic meds, building on one success in US pricing

on May 20, 2026

Amazon Pharmacy Cost Plus Drugs drug price generic medications GoodRx prescription discounts Trump administration TrumpRx

+

Get link
Facebook
X
Pinterest
Email
Other Apps

ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease

on May 20, 2026

acceptance Anktiva BCG-unresponsive Blackfoot language ImmunityBio Non-Muscle Invasive Bladder Neoplasms Papillary Disease PDUFA Supplement United States Food and Drug Administration

+

Get link
Facebook
X
Pinterest
Email
Other Apps

Zydus Lifesciences to Pursue Acquisitions in Specialty and Rare Diseases

on May 20, 2026

acquisitions Assertio Holdings Infrequent non-generic specialty Nulibry portfolio specialty diseases US Zokinvy ZYCUBO Zydus Lifesciences

+

Get link
Facebook
X
Pinterest
Email
Other Apps

Takeda faces possible $2.5 billion damages in Amitiza pay‑for‑delay case

on May 20, 2026

Amitiza antitrust lawsuit Takeda Tissue damage United States

+

Get link
Facebook
X
Pinterest
Email
Other Apps

Akeso Spotlights AML Data for Anti‑CD47 mAb Ahead of EHA 2026

on May 20, 2026

Akeso anti-CD47 monoclonal antibody Anti-CD47 Monoclonal Antibody AK117 azacitidine EHA European Hematology Association Leukemia, Myelocytic, Acute Ligufalimab Phase 2 Clinical Trials venetoclax

+

Get link
Facebook
X
Pinterest
Email
Other Apps

BioMarin's rare disease therapy shows no clinical benefit in Phase 3 test

on May 19, 2026

BioMarin BMN Clinical Benefit Deficiency ENPP1 gene growth Z-score Hereditary Diseases Infrequent inorganic pyrophosphate Plasma prepulse inhibition activity Rare Diseases RGI-C scores Rickets Severities

+

Get link
Facebook
X
Pinterest
Email
Other Apps

Relay presses ahead on PI3Kα inhibitor after first phase 2 data in vascular (blood vessel) disorder

on May 19, 2026

blood vessel disorders Lesion reduction Phase 3 Breast Cancer Trial PIK3CA-driven Relay Therapeutics safety profile Steam Vascular anomaly zovegalisib

+

Get link
Facebook
X
Pinterest
Email
Other Apps

SEED Therapeutics to Present Phase 1 Trial Design for ST-01156, a First-in-Human Oral RBM39 Molecular Glue Degrader, at 2026 ASCO Annual Meeting

on May 19, 2026

advanced solid malignancies Ewings sarcoma KRAS-mutant cancers Liver carcinoma molecular glue degrader RBM39 gene SEED Therapeutics ST-01156

+

Get link
Facebook
X
Pinterest
Email
Other Apps

Clinical trial flaws being scaled, not solved by AI: report

on May 19, 2026

Clinical Trials Data Quality Drug Development flaws patient outcomes Phesi protocol design scaling not solving

+

Get link
Facebook
X
Pinterest
Email
Other Apps

Incyte inks deal with Edison Scientific to train AI through drug discovery

on May 19, 2026

AI scientist Artificial Intelligence Clinical Data Discover Drug Discovery Edison Scientific Incyte Kosmos predictive models R&D Target translational translational biology Validation

+

Get link
Facebook
X
Pinterest
Email
Other Apps

Full-Life Technologies Raises $150M to Accelerate Clinical Assets and Manufacturing

on May 19, 2026

Capital clinical-stage assets financing characteristics Full-Life Malignant neoplasm of prostate Radiopharmaceuticals Series D equity SK Biopharmaceuticals Technology Therapeutic radiology procedure

+

Get link
Facebook
X
Pinterest
Email
Other Apps

AstraZeneca wins FDA nod for first‑in‑class blood pressure pill Baxfendy

on May 19, 2026

aldosterone synthase inhibitor Approved AstraZeneca baxdrostat Baxfendy blood pressure pill Class Hypertensive disease May 18 Uncontrolled United States Food and Drug Administration

+

Get link
Facebook
X
Pinterest
Email
Other Apps

Archive

May 2026152
April 2026257
March 2026233
February 2026175
January 2026261
December 2025151
November 2025147
October 2025222
September 2025190
August 2025161

July 2025130
June 2025159
May 2025174
April 2025191
March 2025205
February 2025198
January 202539

Show more Show less

Tags

United States Food and Drug Administration Clinical Trials Approved Obesity gene therapy Neoplasms Vaccines Glucagon-Like Peptide 1 Investments Artificial Intelligence

Pfizer Pharma AstraZeneca Eli Lilly layoffs Drug Industry Market sanofi Merck Phase 3 Infrequent Roche (company) China Novartis Biological Factors acquisition Drug Discovery Drug Development manufacturing Leadership Autoimmune Diseases CEO restructuring Cell Therapy Appointments SmithKline Beecham Transplant Registry Unified Management Program Acquisition Nordisk IPO eli lilly Biotechnology Wegovy drug price COVID19 (disease) Funding Policy expansion CHARGE Syndrome Inhibitor Safety Weight Loss Novo Nordisk U.S. Centers for Disease Control and Prevention (U.S.) Eli Muscular Dystrophy, Duchenne R&D AbbVie United States semaglutide Antibody-Drug Conjugates Immunology Industry Malignant neoplasm of breast Overall Survival Precision Medicine Partnership Biopharma Zepbound therapeutic autologous dendritic cells Alzheimer 's disease Dosage Forms Keytruda Sales - occupational activity methionine Biogen Drug Approval Immunotherapy financial results Health care facility Prices Board of Directors Regeneron Solid Neoplasm Administration occupational activities CAR-T Changing Collaboration Elevidys Non-Small Cell Lung Carcinoma Oral cavity Phase 3 Clinical Trials biotech Amgen M&A rejection Multiple Myeloma Progression-Free Survival Staff earnings ACIP Cancer Therapeutic Procedure Clinical Research RFK Jr. Weight-Loss Agents innovation Biological Science Disciplines Moderna Myers Trump administration UK public health medicine (field) Antibodies, Bispecific Effectiveness Growth PDUFA Schizophrenia milestone payments Antibodies BioNTech pipeline trends qualifier Accelerated Biological Markers Biosimilars 2025 Malignant neoplasm of lung Phase 2 Phase 2 trial clinical development Bayer Financial cost Gene Modification Gilead J&J Metsera Clustered Regularly Interspaced Short Palindromic Repeats Johnson & Johnson RFK gene Takeda clinical trial failure dosing squibb AI-driven Cardiovascular Diseases Diabetes Medicare Nasdaq Ozempic Phase 3 Trial Pricing Radiopharmaceuticals biopharma genentech production Advisory Committees Dupixent EU Myers Squibb NIH Mouse Phase 2 Clinical Trials Rare Diseases Series Study on Hold competition platform venture capital AI drug discovery Clearance Deferred Gilead Sciences MASH Monoclonal Antibodies Phase 3 trials Programs - Publication Format Q3 US in vivo optimization pharmaceutical manufacturing Advice Dermatitis, Atopic Malignant neoplasm of prostate Ophthalmology specialty Series A Transition Mutation concerns net loss public entity research Agonist Astellas Autoimmune Biosciences Capital Diabetes Mellitus, Non-Insulin-Dependent Failure (biologic function) HHS Kidney Diseases Medicaid RNA supply chain Alopecia Cautionary Warning Colorectal Carcinoma Discontinuation (procedure) Eisai Epilepsy Evaluation Health Policy Legal patent Medical Devices Metabolic Diseases Parkinson 's disease Phase III Revolution Medicines Robert F. Kennedy Senate TNFRSF19 gene government licensing agreement orforglipron pharmaceutical tariffs regulatory tariffs Adverse event Amyotrophic Lateral Sclerosis CDMO Daiichi Duchenne Health Hims Inflammatory Bowel Diseases Leqembi Mounjaro Neuroscience discipline Preventive monitoring RNA Interference Sankyo Small cell carcinoma of lung Telemedicine development aspects federal leadership change melanoma 2026 Antineoplastic Agents Biotherapeutics Bispecific Blackfoot language Boehringer Ingelheim CBER CDER Child Clinical Data Endpoints Flagship Hypertensive disease Immunotherapy for cancer Malignant Neoplasms Malignant neoplasm of urinary bladder Merck KGaA Multiple Sclerosis NDA News [Publication Type] North Carolina Phase 3 trial Recommendation Respiratory syncytial virus Response process Technology acquisitions alpha 1-antitrypsin cash runway cost-cutting diagnostics royalties safety profile submission venture Asthma BioMarin Burning Mouth Syndrome CAR-T therapy CD276 gene CFO Complete Confirmation Efficiency Enhertu Facility (object) Financial savings IGA Glomerulonephritis Insilico Medicine LB-102 Labels (device) Mediation Muscular Dystrophy Myasthenia Gravis Nance-Horan syndrome Pancreatic carcinoma Pauses Pharmacotherapy RNA, Messenger Robert F. Kennedy Jr. Series B cardiometabolic direct-to-consumer obesity drug ovarian neoplasm pembrolizumab regulatory approval Alzheimer 's Benefit Bio Board appointment Cancer Research Cells Chronic disease Clinical Combined Drops - Drug Form Drugs, Orphan Eczema European (ethnic group) Frequency of Responses Japan Johnson and Johnson Leukemia, Myelocytic, Acute Liver diseases MFN Malignant neoplasm of stomach Myeloid Leukemia, Chronic Neurodegenerative Disorders Proteinuria Psoriasis RNA, Small Interfering Rheumatoid Arthritis SMPX gene Series B funding Study models Surgical construction Vaccine Safety Vanda Pharmaceuticals White House alpha 1-Antitrypsin Deficiency biobucks cellular targeting daraxonrasib drug safety drugmakers early-stage financing characteristics healthcare technology immuno-oncology medtech milestones patient deaths strategic alternatives subcutaneous tirzepatide Amylin Antipsychotic Agents Automation BTK inhibitor Breakthrough Therapy Budgets File (record) HIV prevention Hidradenitis Suppurativa Homo sapiens IL31RA gene Idiopathic Pulmonary Fibrosis Machine Learning Makary Manufacture Mutation PCSK9 inhibitor PD-L1 Phase 1b Product containing glucagon-like peptide 1 receptor agonist (product) Progressive Pulmonary Fibrosis Pulmonary arterial hypertension RNA Editing Retirement Risk Scientific Advisory Board Series B financing Severe (severity modifier) Spinal Muscular Atrophy Target Weight maintenance regimen biotech startups cash position commercialization executive order oral SERD patent cliff private equity radioligand therapy ASCO Access Agentic AI BARDA Biomechanical compliance Biotech Layoffs COPD Chief Medical Officer Detection Discover Elderly (population group) Exit Generic Drugs Genomics HIV Identifier Impact food supplement Infant Insmed J.P. Morgan Healthcare Conference JPM26 Licensing Manufacturing Facilities Metastatic castration-resistant prostate cancer NVIDIA Narcolepsy Nation Placebos Prasad Precision - temporal Revenue Sectioning technique Shakeup Small Molecule SpringWorks Stock Surge Surgical aspects T-cell engager Toxicity aspects TrumpRx Ulcerative Colitis Veradermics Withdraw (activity) acute approvals biotech industry cancer drugs cardiometabolic diseases corporate digital health inhibitors merger partnerships portfolio resignation revenue growth ATTR-CM Adult Alkermes Antagonist muscle action Antibiotics Attitude Bankruptcy Bavarian Nordic Blood - brain barrier anatomy Boehringer CHMP CNPV CagriSema Chronic Kidney Diseases Chronic Spontaneous Urticaria Chronic multifocal osteomyelitis Commission Congress (U.S. Legislature) Contraceptives, Oral Contract agreement Cystic Fibrosis Disease Outbreaks Dosage Drug Delivery Systems Europe Extension Eylea Foundayo Gardasil Generalized Glycogen storage disease type II Hematologic Neoplasms Hetlioz Intellia LDL-C Lenacapavir MAHA Mucopolysaccharidosis II Multiple Acyl Coenzyme A Dehydrogenase Deficiency Myasthenic Syndromes, Congenital PAH PREP gene Patient Death Pediatric brand name PhRMA Pharmaceutical Services Phase 1 (qualifier value) Prader-Willi Syndrome Response Letter Review [Publication Type] Roivant Seizures Servier Supplement Trump tariffs VK2735 Wave Life Sciences Wegovy pill aspects of adverse effects asset bidding war biology (field) delays executive appointments giredestrant jet lag disorder lawsuit pharmaceutical innovation precision oncology royalty strategic strategic collaboration treatment-resistant depression trials uniQure upfront payment AAVS1 gene Abivax Agencies Aktis Amlitelimab Anemia Autistic Disorder Biotech IPOs BridgeBio Chief Financial Officer Combined Modality Therapy DNA Integration Diabetes Mellitus, Insulin-Dependent ESMO Enliven Therapeutics Event Evidence Exelixis First line treatment Fund Raising GLP-1 receptor Genmab Germany HPV vaccine Heather Flick Melanson IPOs Illumina Incyte Indirect Indonesian language Inflammatory disorder Influenza Injury of liver LDL Cholesterol Lipoproteins Leukemia Liver Failure, Acute Lundbeck Lupus Vulgaris Maintenance Marty Makary Measles-Mumps-Rubella Vaccine National Security Neuroinflammation Neurology speciality ORR Opdivo Otsuka PD-1/VEGF Padcev Partner in relationship Paul Hudson Pioneering Post-Traumatic Stress Disorder Presenile dementia President brand of dental material Priority Review Projections and Predictions Psilocybin RETINITIS PIGMENTOSA 1 Regenerative Medicine Regenxbio Remote Replimune Retinitis Pigmentosa Secretary Sentiment Statistical Significance TIGIT gene Teva Tolebrutinib Translucent Ultragenyx Vinay Prasad Zealand Pharma biomanufacturing biotech partnerships drug review erbB-2 Receptor exophthalmos producing substance factor IX generative AI generics immunotherapeutics launch manufacturability manufacturing issues mental health monthly oncology pipeline onshoring oral semaglutide patent infringement perioperative personalized therapies pilot program sNDA shipment sonelokimab 3-Methylglutaconic aciduria type 2 AACR 2026 ADC ADCs AKTS ALV-100 ALV-200 AMT-130 Achondroplasia Acquisition (action) Akeso Alnylam Alumis Alveus Therapeutics AnaptysBio Angioedemas, Hereditary Anticoagulants Antisense Oligonucleotides Application procedure Argenx Ascletis Avalyn BCR-ABL1 BNT327 Big Pharma Blenrep Bourla Buckham CE Mark CIDRAP CNS disorder CSO Camzyos Cancer Vaccines Cancer of Neck Cardiovascular system Cessation of life Chronic Lymphocytic Leukemia Cobenfy Complete Response Letter Conditional Crohn 's disease DOGE Deafness Decision Deep molecular response Denali Department of Health and Dependovirus Disorder of eye Drug Prescriptions Durham ESR1 gene Eikon Elamipretide Epidermal Growth Factor Receptor Event-Free Survival Evotec SE Failed Forbion GIPR gene GZMH gene Galapagos Generative AI Geographic Atrophy Gomekli Guanosine Monophosphate HER2-negative Halda Therapeutics Halozyme Hannah Anderson Head Head of US Heart Diseases Heart failure Hepatitis B Hong Kong Huntington 's disease Hyperphagia Immunization Immunostimulating conjugate (antigen) Impaired Import In complete remission India Inflammation Inflation Reduction Act Insulin Ipsen Ivonescimab J.MD Jazz Jr. K-ras Oncogene License Application Licensing Deal LillyDirect Liquid Biopsy Litigation Long-term Lung diseases Lymphoma Malignant neoplasm of endometrium Malignant neoplasm of kidney MariTide-like Maziar Mike Doustdar Menopause Molecular Response MoonLake Most-Favored-Nation Myelocytic NECTIN4 gene NLRP3 inhibitors Nerve Degeneration Nitroglycerin/Sodium Citrate/Ethanol Solution Novavax OpenAI Opioids PDCD1 gene Peptides Performance Phase 1b trial Phase 3 clinical trial Phase I Clinical Trials Platform Project Protein Degradation, Metabolic Q4 2025 R-Series RNA therapeutics RVMD Regulation Relapsing course Research Projects Retinal Diseases Rick R. Suarez Rocket Sandoz Science Score Shanghai Stem Cell Therapy Stock Decline Surveys T-Lymphocyte TMEM79 gene TYK2 gene Tagrisso Talzenna Tecentriq Triple Negative Breast Neoplasms Tubulis Twice a day Type B meeting Uncertainty Vaccine Integrity Project Vascular Endothelial Growth Factor A Ventyx Biosciences Viking Virginia manufacturing facility WDR20 gene Wilmington Delaware Window (physical object) Winrevair Worker aldosterone synthase inhibitor analysts annual asciminib assets baxdrostat chain disruption collaboration termination dealmaking decision letter deruxtecan developability disbanded drug discounts drug market engagers enzalutamide financial first focal onset seizures funding grant human independent review interleukin-6 license agreement mRNA Vaccine manager minoxidil molecular glue nivolumab obesity pill phase advance protocol preclinical data protein degrader public health policy real-world recommendation change regulatory submission regulatory uncertainty reorganization settlement shareholder single-dose schedule small-cell lung cancer startup stocks strategic review summit surge survival targets tasimelteon user fees 2023 340B AACR AI drug development AI platform AI-powered AP01 Adolescent (age group) Affordability Alcon Alexion Altimmune Androgenetic Alopecia Anemia, Sickle Cell Anktiva Antibody-Drug Apellis Arvinas Asymmetric Septal Hypertrophy Atrial Fibrillation Audit Committee Australia Autoimmune thrombocytopenia B-Lymphocytes BEACON-IPF Bain Capital Beyfortus Billion Biologics License Application Biomedicines Blindness Board Appointment Bovichtus Brain Neoplasms Brazil Breakthrough Therapy Designation Brinsupri CDC CDE CEOs COVID CVR California Cambridge Canada Capricor Therapeutics Capsid Carcinoma breast stage IV Carlyle Chief Chief Legal Officer Childhood Vaccines Chinese Language Chronic pain Clinical Failure Clinical Nurse Specialists Co. Compass Pathways Contraceptives Corporate governance Cytokinetics CytomX DKK1 gene DMD DNA Datroway Diabetic Retinopathy Dianthus Therapeutics Diffuse Large B-Cell Lymphoma Disease-Free Survival Ditiocarb Diversity Drug Regulations EBITDA ELAVL2 gene ER-positive Ebvallo Effect Eli Lilly backing Enflonsia Engaged to be married Episodic Family Turdidae (organism) FibroGen GLP-1/GIP dual agonist GLP-1s Gene Silencing Glaucoma Gubra Hallucinogens Healthy Hearings Hemoglobin A1c measurement Hot flushes IL33 protein, human IRA ImmunityBio Immunogenicity (package insert) Immunovant Increase InduPro * * Infantile Severe Myoclonic Epilepsy Injectables Inosine Triphosphate Insurance Ionis Pharmaceuticals Ira (eukaryote) JPM Journavx Kailera Legal Letter [Publication Type] Liver Lynkuet M&A activity MYELODYSPLASTIC SYNDROME MacroGenics Macular edema due to diabetes mellitus Malaria Medical Research activity Mental deterioration Merck & Co. Migraine Disorders Misinformation Mississippi (geographic location) Muscular Dystrophies, Limb-Girdle Myocarditis NAMs NYSE Nektar Therapeutics Neurocrine Neuropsychiatry New Drug Application New Jersey ODAC Odyssey Therapeutics Ogsiveo Oligonucleotides Oral Organoids PD-1xVEGF Pathology Patient access Pennsylvania Peter Marks Phase 2 clinical trial Phase 2 trials Phase 2b Phase I Plant seeds Pliant Pounds Praxis Precision Medicines Preclinical Prediction Preventive Health Services Primary Biliary Cholangitis Protac Q1 2026 Q2 2025 Q3 2025 Quality RAS-driven cancers RGX-121 RIPTAC RMAT Rakovina Real-world Evidence Recursion Regulatory Setback Research Personnel Reversal Rinvoq Robotics SanegeneBio Seqirus Series D Series D financing Small Interfering Sotyktu Stealth BioTherapeutics Structure Therapeutics Subcutaneous Injections Suspensions TMALIN TSLP gene Terns Transitory Triglycerides UX111 Urinary tract infection VDPHL01 VTX3232 VTX958 Vaccination Validation Valneva Vas Narasimhan ViiV Healthcare Vinay Vital capacity Vyvgart Wall Street Journal Workforce Reduction YL201 Yeztugo Zolgensma Zorevunersen Zymeworks agonists alfa alixorexton antitrust authorization biotech collaboration biotech sector bis(3-bis(4-chlorophenyl)methyl-4-dimethylaminophenyl)amine board changes bounce business career capital markets chief of chikungunya vaccine chronic clinical endpoints conditions contingent value right court deals decline departure - ActRelationshipType digital transformation domvanalimab enforcement enlicitide executive leadership expense federal judge leukemia mCRPC measles muscle preservation muscle-invasive bladder cancer negotiation nrSPMS pandemic preparedness patent settlement pharmaceutical companies pharmaceutical marketing pharmaceutical sales pharmaceutical supply chain proposal - intent protein degraders radiopharma rally ras Oncogene rates real-world data real-world evidence regulatory compliance remibrutinib reshoring resubmission retatrutide rumors shionogi shutdown skipping spending stock crash takeover talks talazoparib targeted therapies tariff trastuzumab upadacitinib user fee value-based care venetoclax women 's health workforce reduction zanzalintinib 130-nm albumin-bound paclitaxel ABVX AI biotech AI healthcare AI model AI models AI protein design AI-designed drug AI-enabled ALS AP02 ARD-101 ASC30 ASGCT ATR Inhibitor Aardvark Therapeutics Acceleration Acelyrin Acute lymphocytic leukemia Acute onset pain Adjuvant Therapy Advanced phase Advocacy Age related macular degeneration Agios Albert Alector Alternative Americas Amylin Analog Amyloid beta-Peptides Angelini Pharma Antengene Anthropic Antiviral Agents Apellis acquisition Apolipoprotein E4 Apolipoproteins B Arcellx Arcus Arcus Biosciences Arrowhead Pharmaceuticals Ascendis Pharma Assembly (construction) Atara Ataxia Aurora Therapeutics Autoimmune hemolytic anemia Automobiles Avidity Biosciences Awareness B-Cell Lymphomas BeOne Medicines Beak Beijing Bhattacharya Biktarvy Biliary Tract Cancer Biohaven Biomedical Research Black Populations Blood Coagulation Disorders BlueRock Therapeutics Blujepa Body mass index procedure CBO CD19 Antigens CD3 Antigens CDK2 protein, human CLL CNP gene COAST COMP360 CRDMO CRLs CRO Carboxyamidotriazole Orotate Cardiff Oncology Cardiomyopathies Casgevy Cash Cerebrovascular accident Cervical Atlas Change, Organizational Charles Chief Operating Officer Chikungunya Fever Childhood Chugai Clinical Trial Design Clinical Trial Failures Complete Response Letters Compound Concentra Biosciences Congenital Construction worker CordenPharma Crackdown Creative Biolabs CureVac Cylembio Cystic Fibrosis Transmembrane Conductance Regulator Darzalex Datopotamab deruxtecan Deal Value Death of child Depletion Dexcom Diabetes Mellitus Disease Progression Does speak Drug Shortage Drug withdrawal syndrome DualityBio Dyslipidemias Dystrophin ECCO ENTR-601 Earendil Labs Emma Walmsley Empaveli Employee Endometriosis Expectations Express Scripts Eylea HD FCGRT gene FDA-approved Fabry Disease Familial chylomicronemia syndrome Farxiga Fast Track Fierce Florida Freezing Funds Fyodor G-Protein-Coupled Receptors GE HealthCare GLP-1/GIP Gastric Inhibitory Polypeptide General Meeting Genome Glycogen Storage Disease Type IIb Glycosylated hemoglobin A Groups HHS layoffs HLD-0915 Hemab Therapeutics Hematologic Tests Hereditary Diseases Hims & Hers Hodgkin Disease Holdings Holly Springs Hormone Therapy Hyperphosphatemia (disorder) Hypertriglyceridemia Hypertrophic Cardiomyopathy Hypertrophic obstructive cardiomyopathy Hypothalamic obesity Imcivree Imdelltra Imfinzi Immune Medicines Immunome Improvement Indication of (contextual qualifier) Inflation Influenza virus vaccine Ingelheim Inhibrx Interferes with Isomorphic Labs Ixchiq Janus kinase Jaypirca Jeffrey Jennifer Doudna Kailera Therapeutics Kinaset Therapeutics Kirin Kisunla Kymera Kyowa Labcorp Laboratory Laboratory test finding Lecanemab Legos License Litifilimab Liver Failure Liver carcinoma Logistics Longevity Lp(a ) Luke Miels Lupus Erythematosus Lupus Erythematosus, Systemic Lymphoma, Follicular MC4R protein, human MET-097i MHRA Madrigal Pharmaceuticals MapLight Therapeutics Maria Sainz Marty Maryland (geographic location) Medical service Medicare Part D Menin Inhibitor Menkes disease Menlo Ventures Mental Depression Merus Metabolic Midline (qualifier value) Mortality Vital Statistics Motion Sickness Muscular Dystrophy, Facioscapulohumeral Myasthenia Gravis, Generalized Myasthenic Syndromes Myopia NIH Narcolepsy type 1 Nasal Spray Neoplasm, Residual Neurodevelopmental Disorders Neuromuscular Diseases Neurosecretory Systems New Nkarta Non-Insulin-Dependent Non-Muscle Invasive Bladder Neoplasms Novavax 's Nucala Nxera Pharma Obesity Drug Odyssey PARP1 gene PFS Pain management Parity Pediatric Disorder Personalized Personnel Turnover Pharma Industry Pharmaceutical merger Pharmacovigilance Phase Phase 1 trial Phase 1/2 data Phase 1/2 trial Phase 3 failure Pipeline Development Post-Hoc Live PreCheck Precision immunology Pressure- physical agent Primary Prevention Privacy Protein-tyrosine kinase inhibitor Proteomics Prothena Psychological inhibition Psychotic Disorders Public Offering Pulse Biosciences R&D pipeline RAP-219 RAS REMS Rapport Therapeutics Reaction Recovery - action Recurrent respiratory papillomatosis RegenXBio Regulatory Action Regulatory Affairs Reimbursement RemeGen Repatha Repertoire Respiratory physiology Restrictions Revenue Decline Rexulti Rezpeg Rhythm Pharmaceuticals Richard Pazdur Rocatinlimab Rosnilimab Rybrevant SLC6A8 Inhibitor RGX-202 SPAC San Diego Saxenda Scholar Rock Science of Chemistry Screening for cancer Secretary Nomination Security - service Senate hearing Series A financing Sharing (Social Behavior) Shingrix Sibeprenlimab Skyrizi Sofinnova South San Francisco Spikevax SpinCo ' Spinocerebellar Spinraza Stabilizer - function Stelara Subgroup A Nepoviruses Substance Use Disorders Supernus Pharmaceuticals Syfovre Systemic Systemic Scleroderma T-Cell Receptor T-cell engagers TERN-701 TNBC TREM2 TUB-040 Takeover Tavneos Tessera Therapeutic immunosuppression Thermo Fisher Thermo Fisher Scientific Thyroid associated opthalmopathies Tradipitant TransCon Transection (procedure) Trimonthly Trodelvy Trump Truqap UPenn Unable to walk (finding) Uncontrolled United Kingdom United States National Institutes of Health UnitedHealth Group Unresponsive to Treatment Uplizna UroGen VAERS VG-3927 VRBPAC VX-264 Vabysmo Vepdegestrant Verona Viking Therapeutics Viral Vector Vision WVE-007 Winter Park Workers World Health Organization WuXi WuXi AppTec Xtandi Zenas BioPharma Zurzuvae abbott adaptation addiction advanced therapies aficamten amendment asthma drug atezolizumab azacitidine bemdaneprocel benzamide antipsychotic benzamide class bexotegrast binding affinity biotech acquisition biotech merger branded drugs brensocatib calcium glucarate camizestrant cancer care cancer drug development capabilities checkpoint inhibitors childhood vaccine schedule clinical pipeline commercial commercial strategy constraints data integration datasets deal degraders deramiocel deucravacitinib digital pathology digital twins direct-to-consumer sales discontinued discount domestic manufacturing draft guidance drug acquisition drug efficacy drug manufacturing drug shortages election equity exon federal funding federated learning fibroblast growth factor 21 first-line gMG genetic medicines gepotidacin governance headquarters healthtech high-risk iTeos ianalumab ifinatamab inhaled therapy investor itepekimab language models mRNA Vaccines mRNA flu meeting mergers mimetics mitapivat nPulse nerandomilast nervous system disorder neurological diseases nex-z next-generation obesity trial obinutuzumab once-daily oncology partnership onvansertib operating profit oral therapies oral treatment orexins ounce outcomes oveporexton pacibekitug partnership termination patented drugs patient death payers payment payments pharmaceutical acquisition pharmaceutical partnership pipeline reduction platforms platinum-resistant pre-funded preclinical programs prescription drug costs primary endpoint psychedelic therapy public trust pumitamig refusal regulatory guidance regulatory science research collaboration reverse merger review extension rezpegaldesleukin roxadustat safety review scalability second-line treatment seed fund setmelanotide shareholders skepticism small molecule therapeutics specialty medicines statutory scheme stock drop strategic partnership strategic partnerships strategic restructuring strategic shift succession terminations therapeutic protein tolerability travel trial design triple agonist twice-yearly injection type 2 inflammation update upfront vaccine overhaul vaccine schedule valproic acid glucuronide valuation vedotin virtual care 15% 75% 8 AACR25 AAV Vector ABBV-295 ABI-5366 ACR gene ACTN4 wt Allele AERIFY-1 AERIFY-2 AFFINITY DUCHENNE AH 001 AI Platform AI drug design AI factory AI health AI platforms ALK gene AMD AMG AML ANCA vasculitis ANGPTL3 AOC AP306 ASCVD ATG-201 ATTD ATTRv-PN AVLN Abeona Abnormality of mitochondrial metabolism Acadia Accurate (qualifier) Actinium Adaptimmune Administration of prophylactic statin Administrative action Adoption AdvanCell Adverse effects Adverum Biotechnologies Advisory Panel Age AgomAb Agreement Alagille Syndrome Alameda Headquarters Aldeyra Alfasigma Allogene Alzheimer 's psychosis Amazona Ambulatory Care Facilities Amicus Therapeutics Amplia Amvuttra Amyloidosis AnHorn Medicines Analgesics Analgesics, Non-Narcotic Antibody Therapy Antimicrobial Resistance Antistreptolysin O Anxiety Disorders Apnimed Appia Bio Apple Watch Apply Arbutus Arenaria <Aves> Arrowhead AsedaSciences Asia, Southeastern Atacicept Atopic Attention deficit hyperactivity disorder Attruby Aurinia AutoInjector Autoantibodies Autologous Anti-BCMA-CAR-mRNA-transfected CD8+ T-lymphocytes Avadel Pharmaceuticals Availability of AviadoBio Avlayah Axpaxli Ayrmid Azafaros B-cell depletion BCG-Unresponsive BGM0504 BMS BNC210 BRUIN Base Editing Batoclimab Baxfendy Bay Area Beam Therapeutics Behavior Big Beautiful Bill Bill Anderson Bill Cassidy Bio-Rad BioAge BioCapital BioNTech 's BioNeMo Biochemical Pathway Biological Assay Biopharma Advisory Board Biopharma Sentiment Index Biopharma layoffs Bioscience Biotech Innovation Black Box Warning Blackstone Blackwell GPUs Blood Pressure Bluebird Bio Boston Scientific Breakout Ventures Brepocitinib BrightGene Bronchiectasis Bruton 's tyrosine kinase inhibitor Buyout CAN-2409 CD19xCD3 CD388 CDK4/6 inhibitor CELMoD CGM CHF CLN-978 CMPX COMPANION-002 CORALreef CORALreef AddOn COVID-19 Vaccines CPOX gene CRL CRSwNP CSU CT-996 CTSC gene CUTX-101 Cadence OTC Cancer Detection Candel Therapeutics Candidiasis, Chronic Mucocutaneous Capacity Capillary Leak Syndrome Capital Management Capital Partners Caplyta Cardamyst Cardiology discipline Cardiovascular Agents Cardiovascular Risk Cardiovascular event Cartesian Cartography Biosciences Carvykti Cash Crunch Catalent Catalent Indiana Cataplexy Cavazzoni Celcuity CellCentric Celltrion Center for Drug Evaluation Centessa Pharmaceuticals Central Core Myopathy (disorder) Cerebral Edema Chairperson Challenge Chancery Charles River Laboratories Chickenpox Chief Business Officer Chief Commercial Officer Chief Product Officer Chief Technology Officer Chimeric Antigen Receptor T-Cell Therapy China-based Chinese biotech Cholestatic pruritus Chris Klomp Christophe Weber Chronic inflammatory disorder Chronic low back pain Chronic neutropenia Chronic sinusitis Cidara Therapeutics City of Boston Cityblock Health Clinical Advisory Board Clinical Decision Support Clinical Oncology Clinical Services Clinical action Clinician Closed Cogent Biosciences Columvi Commissioner Commissioner 's National Priority Voucher Community Company Split Comparative Efficacy Compass Therapeutics Complicated Compounders Comprehensive Conferences Confirmatory Trial Consultation Consumer Safety Continuous Glucose Monitoring System Continuous glucose monitoring Contract Research Organization Conventional (Clear Cell) Renal Cell Carcinoma Corcept Corcept Therapeutics Cosentyx Country Covid vaccine Crohn 's & Colitis Congress Cullinan Customer Cutaneous DB-OTO DEI DEL-AI DELIVER (veterinary product) DILI DLL3 gene DMPK gene DNA Replication DNA medicines DOJ DOR/ISL Daily Dapiglutide Darovasertib Darzalex Faspro Data Analysis Data Quality Data Safety Daytime Somnolence De Novo Deep Apple DeepHealth Deerfield Management Deficiency Degrader Delaware Delaware Court Deloitte report Dental Plaque Depression Depression, Bipolar Depression, Postpartum Depressive disorder Deramiocel Dermatitis Dermatologic disorders Dermatology field Dermatomyositis Diagnosis Diagnostic Imaging Disease remission Donald Trump Dopaminergic Neurons Dordaviprone Dr. Droughts Drug Approval Process Drug Costs Drug Design Drug Formulation Process Dry Eye Syndromes Dwarfism Dyne Therapeutics EASI EASI-75 EGFR-mutated EHA EMA EMBARK trial EMMI ENPP1 gene ESMO Congress EV-304 EZH2 protein, human Early Diagnosis Economics Ecosystem Edema Electrophysiology (science) Eligibility Determination Eliquis Elivaldogene autotemcel Elon Emergency Contraception Employment Termination Endo Entrada Enveda Environment Enzymes Epcoritamab Epigenomics Erasca Escherichia coli Esperion Etavopivat Evaluation procedure Evernorth Evotec Excessive (qualifier value) Exdensur Executive Chairman Eye FIBRONEER-ILD FLAURA2 trial FY2025 Fabhalta Fair Language Proficiency False Claims Act Familial mitral valve prolapse FcRn Federal Circuit Feedback - system communication Fertility Agents Fertilization in Vitro Fibrodysplasia Ossificans Progressiva Fibromatosis, Aggressive Fibromyalgia Fibrous histiocytoma of tendon sheath Financial Forecast Revision Flatulence Focal Food Safety Force Fortress Forzinity Foster City Fosun Pharma Fragile X Syndrome France Fraud Friedreich 's ataxia Fujifilm Functional Futility GABA Modulators GEP-NETs GLP-1 pill GLP-1/GIP receptor agonist GS-1720 GS-4182 Gaithersburg Gastrointestinal Stromal Tumors Gazyva Gemini of Coiled Bodies Gender Gene Expression Gene Mutation Generic Competition Genetic Medicine Genetic Profile Genome Editing Genrix Bio George Tidmarsh Glioblastoma Goldcrest Goldman Sachs Gonorrhea GoodRx Google Cloud Govorestat Grail Gram-negative bacteria Guidelines HBr HELP Committee HER2-mutant HER2-positive carcinoma of breast HFpEF HIBISCUS trial HIV sales HOPE-3 trial HRS-5346 HRSA HYMPAVZI Hallopeau-Siemens Disease Harbour BioMed Health Care Market Health Care Reform Health Personnel Health Planning Health agencies HealthBench Healthcare AI Heart Helicon peptide platform Hemophilia A Hengrui Hengrui Pharma Hengrui Pharmaceuticals Hereditary Coproporphyria Herpes zoster disease High High-Throughput Nucleotide Sequencing Hikma Pharmaceuticals Hillhouse Investment Management Home environment Hong Kong NDA Hospitalization House mice Hua Medicine Humira Hyderabad Hypercholesterolemia Hypercholesterolemia, Familial Hyperlipidemia Hypersensitivity Hypoimmune Technology Hypoparathyroidism I-DXd ICOTYDE IDeate-Lung02 IGFBP7 gene IGNYTE trial IMNM IMVT-1402 ITM-11 IZERVAY Iambic Therapeutics Ibex Medical Analytics Ibrance Ideaya Biosciences Idorsia IgG4-Related Disease Imaavy Imbruvica Immune Immune System Diseases Immune Tolerance Immune response ImmuneOnco Immunization Schedule Immunoglobulin IgG4 Immunology pipeline Immunoregulation Impaired cognition Increased Incretins Individual Adjustment Induce (action) Infantile Neuroaxonal Dystrophy Infinimmune Infusion procedures Injection of therapeutic agent Innovent Biologics Inobrodib Insitro Inspection (procedure) Intact Intellectual Property Intelligence Interim Interleukin-13 Interleukin-17 Interval Intra-Cellular Therapies Intrathecal Route of Drug Administration Invasive Invasive meningococcal disease Inventiva Investor Reaction Io satellite Irish (ethnic group) Isomorphous J&J 's JCR JNJ-4496 Japanese language Jay Jay Bhattacharya Jemperli Johns Jon Congleton Jorna Judge KEYNOTE-B15 KGaA KOL KOL Bulletin KOMET-001 KRP KRP-M223 KRRO-110 KRSA-028 KT-621 KYV-101 Kai Beckmann KalVista Karyopharm Therapeutics Kelonia Therapeutics Kennedy Kerendia Kevin Tang Kezar Life Sciences King Kisqali Korro Bio Korsana Biosciences Kresladi Kyorin Kyowa Kirin Kyverna LAVA LBRX LEAP LGBTQ+ LUMRYZ Lab-in-the-Loop Lars Fruergaard Jørgensen Late stage Laurie Stelzer Lawyer (occupation) Lazcluze Leadership Transition Lean Mass Legend Biotech Leukocyte adhesion deficiency type 1 LifeMD Lifting Lightning Step Lila Sciences Lilly Gateway Labs Lilly collaboration Linerixibat Lipid Nanoparticles Liver and Intrahepatic Biliary Tract Carcinoma London Long Intergenic Non-Protein Coding RNA Lonza Lupus Erythematosus, Cutaneous Lupus Nephritis Lyme Disease Lytenava MAGNITUDE trial MASP-3 Inhibitor MBX Biosciences MEK MEMO1 gene MET-233i MPLT MRGPRX2 gene MRT-6160 MSTAR MYOTONIC DYSTROPHY 1 Mabwell Malignant neoplasm of anus Mallinckrodt Mantle cell lymphoma MariTide Massachusetts (geographic location) Measures Mechanism Framework MedKey Medical Specialities Meeting Mehmet MeiraGTx Mendra Meningococcal vaccine Mental Recall Mesenchymal Stem Cells Metabolic Syndrome X Mexico Microbicides Microbiome Microglia Microsoft Midomafetamine Mike Doustdar Milestone Miller Dieker syndrome Mineralys ModeX Molecular Glue Degrader Monte Rosa Therapeutics Monthly (qualifier value) Morning After Pill Mother (person) Mozafancogene Autotemcel Mucopolysaccharidosis Type IIIA Multiple Sulfatase Deficiency Disease Musk secretion from Musk Deer Mycoses Myeloid cell engager Myotonic Dystrophy Myqorzo NBD1 NEJM NEREUS NPM1 Nasdaq EIKN Nasopharyngeal carcinoma National Priority Voucher Neoplasm Metastasis Nephrology Speciality NervGen Pharma Neuphoria Neuregulins Neurodegeneration Due To Cerebral Folate Transport Deficiency Neuroendocrine Tumors Neurofibromatosis 1 New Approach Methods NewAmsterdam Pharma NewCo Newleos Nimbus Therapeutics Note (document) Novo Novo Nordisk Foundation Nurix Nuvalent OBBBA OPKO Health OTOF gene Obefazimod ObesityWeek 2025 Obexelimab Obicetrapib Obstetric Delivery Ocular Toxicity Olezarsen OliX Omeros Oncolytics Opdualag Open OpenFold3 Optogenetics OrbiMed Orca Bio Orexin Receptor Agonist Organization administrative structures Organon Ornithine carbamoyltransferase deficiency Orphan Drug Designation Orthopedics Oura Ouro Medicines PANSS PD-1/VEGF bispecific antibody PD-L1xVEGF PHD1/2 inhibitor PLK1 gene PLN-101095 PLRX PM359 PP405 PTC518 PWS PYRUKYND Papzimeos Parabilis Medicines Paragon Therapeutics Parkinson Disease Paroxysmal supraventricular tachycardia Partial Parts per million (qualifier value) Patent extension PathAI Paul Offit Penmenvy Pericardial effusion Personalized cancer care Personnel Selection Persons Petosemtamab Phage Therapy Pharma AI Pharmaceutical Research Pharmacy facility Phase 1/2a Phase 2a trial Phase II Phase II B Trial Philadelphia Philips Phobia, Social Physical and emotional exhaustion state Physicians Pick Disease of the Brain Pierre Fabre Pipeline Progress Pirtobrutinib Pivot Device Plexiform Pliant Therapeutics Pluvicto Podnosis Poly(ADP-ribose) Polymerase Inhibitors Poolbeg Post-transplant lymphoproliferative disorder Postpartum Precigen Prediabetes syndrome Predictive analytics Pregnant Women Presentation Preventive Care Primary Health Care Primary Hypersomnia Primary Myelofibrosis Primary amyloidosis Prime Medicine Principles Priovant ProfoundBio Progranulins Project NextGen Promotion (action) Protein Degradation Protein Engineering Protein Tyrosine Kinase Proteins Protocols documentation Prussia Psoriasis Area and Severity Index Clinical Classification Public Preparedness Pulmonary Pulmonary Hypertension Q1 2025 QIAGEN Quality of life Qyuns Therapeutics R1 Therapeutics RAPT RC148 RDEP RECONNECT RGX-111 RNA, Circular ROS1 gene RP-A501 RSV RadNet Radiant heater Rani Therapeutics Ras Inhibitor Recruitment Recursion Pharmaceuticals Relapse Relocation of home or business Renal Cell Carcinoma Reparative closure Republican Republicans Respiration Disorders Response Letters Retinal Vein Occlusion Rett Syndrome Revenue Upgrade Rezdiffra Rezpegaldesleukin Rhapsido Rigel Pharmaceuticals Rilzabrutinib Rising Risk Management River Laboratories Robert Langer Rogaine Romvimza Rybelsus Rytelo SA030 SABCS SG&A SNCG gene SOPHiA GENETICS SPN-820 SPS STAR-221 STARGLO STAT6 degrader STELLAR-303 SV Health Investors SVP SYMPHONY-1 trial Salts Samsung Samsung Biologics Saphnelo Sarcoidosis Scemblix Schrödinger Scientific Study Scott Gottlieb Seaport Therapeutics Sebetralstat Self Confidence Senate Finance Committee Sense of identity (observable entity) Sentynl Therapeutics Septerna Series C Sernova Services Shockwave Medical Sidewinder Therapeutics Simcere Sionna Site SkySTAR platform Skyhawk Skysona Sleep Sleep Disorders Social Welfare Social stigmata Sodium Channel Blockers Soleno South Korea Spinal Cord Injuries Spinout St. Louis Standard (qualifier) Standard of Care Steroids Stewardship Stiff-Person Syndrome Stock Crash Stock exchange Stoke Therapeutics Subcutaneous Keytruda Sun Pharma Sunwave Super Bowl ad Supreme Court Sustained-release Mitomycin C Hydrogel Formulation UGN-102 Suzetrigine Svalbard Switzerland Symbravo Synthetic Biology Synthetic Lethality Syringes TALAPRO-2 TAR 200 TCE TERN-601 TNFRSF4 gene TNFSF15 gene TP53 gene TPTE2 gene TROP2 TSND-201 TSRA-196 TUB-030 Tabelecleucel Tablet Dosage Form Taiho Taiwan Targeted Protein Degradation Targeted Therapy Tazverik Team Tecartus Tecelra Tecvayli Telix Tempus AI Tenaya Therapeutics Tension Terray Therapeutics Texas Thalassemia Theranostics TimeLine Fluoride Releasing Resin Transaction Transcend Therapeutics Translarna Treatment Protocols Treeline Tremfya Trontinemab Trulicity Trump drug pricing Trump loyalists Trump vaccine schedule Tryngolza Tuberculosis TuneLab Type 2 U.S.-China UAE UBT251 UCB UGX-202 US tariffs USPSTF Union United States Federal Trade Commission United States Health Resources and Services Administration United Therapeutics Universities Unnatural Products Unsolicited Adverse Event VANQUISH-1 VERVE-102 VESALIUS-CV VIKTORIA-1 VTCN1 gene Vaccine Development Vaccines, Combined Valo Health Varseta-M Vascular Diseases Vaxart Venclexta Ventus Therapeutics Veppanu Vera Therapeutics Verona Pharma Vigil Vimkunya Vir Biotechnology Vykat Vykat XR Vyndamax Vyne WEE1 gene WVE-006 Wages Wakefulness Walmart Pharmacy Wayrilz Welireg Wellcovorin Woman Workforce - population group Wugen XLRP YUVIWEL Yale Yescarta Ypsomed ZEVASKYN ZYCUBO Zag Bio Zai Lab Zaltenibart Ziftomenib Ziihera Zimmer Biomet Zydus Lifesciences Zynlonta Zynyz access program acute liver injury acute pain treatment ad campaign agentic AI algorithm all-stock alpha therapies alpha-Synuclein altretamine/cisplatin/cyclophosphamide protocol amisulpride anti-IgE anti-seizure medication anti-tumor activity antiarrhythmic peptide antibody libraries antitrust lawsuit apitegromab appeal at-risk augmented avacincaptad belrestotug benzamide bezuclastinib biopharma executives biopharmaceutical development biopharmaceutical industry biopharmaceutical manufacturing biotech closures biotech downturn biotech partnership biotech startup biotechs bispecific ADCs black box blockbuster drugs blood thinner board chair bone health bota-vec boxed bretisilocin brexpiprazole business development buyback cabozantinib campus cancellation cancer discovery cancer pipeline capitalization capsule (pharmacologic) carbetocin cardiometabolic disease cardiometabolic health cardiovascular pipeline care activity cell line development cell renal cell carcinoma charge amounts checkpoint inhibitor cholesterol chronic hand eczema cibotercept claims claseprubart clinical program clinical strategy clinical trial design clinical trial termination clinical-stage assets cold chain logistics companion diagnostic competitiveness compounding pharmacies continuous glucose monitor contract manufacturing corporate strategy cost management cost-cutting measures coverage - financial contract danuglipron data manipulation data privacy day dazucorilant deadline debt decentralized denosumab departures dexamethasone diabetes care diabetes drug diranersen direct-to-patient disease prevention disease treatments disruption divestment dividend domestic drug manufacturing domestic partnerships dorzagliatin dosed dostarlimab drug applications drug development halt drug launches drug rejection drug response drug spending drug-resistant epilepsy dry AMD dupilumab durability economic impact envudeucitinib epigenetic reprogramming etripamil exacerbations executive appointment executive promotions executive transition executives exemptions expert fast-track approval felzartamab fentanyl crisis fill-finish financial performance firings first-in-class first-in-human first-line therapy gastroesophageal adenocarcinoma gedatolisib gene targets generic pharmaceuticals global expansion glucagon glucokinase activator goal growth outlook growth strategy guidance cut hair regrowth health data health disparity heart health high-risk groups high-throughput screening human antibody human papillomavirus hydrocortisone iRhythm iberdomide ibogaine icotrokinra impairment charges import alert improvements incretin drugs inebilizumab injunction interleukin-23 investors islet isononanoyl oxybenzene sulfonate issues leader leadership appointments leadership shakeup leases leucovorin lexicon liraglutide liver transaminase lobbying lorigerlimab losses low-grade mRNA cancer mRNA therapies macrocyclic peptides manufacturers manufacturing capacity masetecan mass layoffs mechanism pathway medical AI medical technology meloxicam merger agreement methodologies mid-stage trial milvexian mirdametinib mitomycin mo-rez mocertatug molecular glue degraders molecular glues multimodal AI multispecific antibodies namilumab narmafotinib navepegritide net income net sales next-generation biologics nivisnebart nomination non-opioid pain drugs oHCM older once-monthly operational oral drug oral obesity drugs oral peptides oral small molecule oral therapy p300/CBP inhibitor patent cliffs patient outcomes patient safety pegcetacoplan pegol pegozafermin pemvidutide persevERA personal reasons personalized cancer petrelintide pharma innovation pharma partnerships pharma revenue pharmaceutical competition pharmaceutical litigation pharmaceutical manufacturers pharmaceutical negotiations pharmaceutical partnerships pharmaceutical regulation pipeline cutbacks pipeline focus pipeline pivot pipeline prioritization pirfenidone placebo-controlled trials platform technology designation plunge point-of-care portfolio strategy povorcitinib predictive models prepulse inhibition activity prescription discounts price cut prime editing priority review vouchers private placement probationary workers product profit guidance protein design protocol design quality management real-time monitoring reality rebound recipients recombinase reconciliation recurrence prevention registrational development regorafenib regulatory challenges regulatory decisions regulatory environment regulatory filing regulatory filings regulatory policy regulatory review regulatory setback regulatory strategy relacorilant removal technique repeal reproductive healthcare reproxalap requirements research funding reshuffle resilience revenue guidance rezetecan ribupatide risk mitigation risk-benefit analysis rizatriptan sacituzumab tirumotecan sales growth seconds sertraline sevabertinib site closures small molecule therapy solbinsiran sparsentan spindle orientation checkpoint startups stop work strategic brands strategic realignment subcutaneous delivery subcutaneous formulation subscription program sustainability synergies tafamidis taletrectinib tariff exemption tazemetostat tenosynovial therapeutic areas thimerosal third quarter 2025 threat tividenofusp topline tourmaline tovecimig treatment failure treprostinil palmitil inhalation powder trispecific antibody troriluzole tumor targeting tumor-activated tumor-selective antigens uridine triacetate ustekinumab uveal melanoma vaccine access vaccine deaths vaccine panel vaccine politics vaccine sales varsetatug vasomotor symptom vatiquinone velinotamig vepdegestrant vera vomiting prevention vormatrigine voucher program vusolimogene oderparepvec warning letters webinar weight-loss weight-loss pill wet age-related macular degeneration winners wound care xRNA zimberelimab zimislecel (3beta * * European Life Sciences Coalition * * Global Expansion * * * * Riad Mishlawi * * * * Vivek Ramaswamy * * * * atopic diseases * * * * functional cell 10 mg 100% 15B 1964 2-aminoethylmethyl sulfone 20% 200 2024 2026-2035 2032 22C3 24-Hour Data 3-(2-methoxyphenyl)-5-methoxy-1,3,4-oxadiazol-2(3H)-one 30% 4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-3-indacene 4D Molecular Therapeutics ' 5,6-methylenedioxy-2-aminoindane 50–59 52-week results 55% 5B 5alpha)-isomer 6-amino-1-hydroxyhexane-1,1-diphosphonate 7.5 mg 8(a 8.875% 80% 90% 95% A&B/SARS-CoV-2 AA Signature AAAAI AACR-NCI-EORTC AAD AAER AAPS NBC 2026 AARD gene AAV antibodies AAV gene therapy AAV-AIPL4 AAV-based gene therapy AAVB-081 AAVantgarde AAVrh74 AAVrh74 vector AB-1005 AB-2100 AB001 ABI-4334 ABPI ABS-0871 ABS-1230 ABTECT-1 ABTECT-2 ACCENT trial ACCESS II ACHIEVE-1 ACI-7104.056 ACP-101 ACR-2316 ACUA AChR-Ab AD109 ADA25 ADAM11 protein, human ADAMTS-5 ADAPT-PD study ADARx ADEL ADEPT-2 trial ADMET ADPD AFFINITY DUCHENNE trial AFFIRM-1 AFFIRM-1 phase 3 trial AFPs AHA AI Assist AI Factories AI Proteins AI Stethoscope AI agents AI antibiotic discovery AI automation AI biomarker AI biopharma AI clinical trials AI guardrails AI health app AI healthtech IPOs AI humanoid robots AI imaging AI lab AI oncology imaging AI safety AI scientist AI skills AI solutions AI supercomputer AI therapeutics AI tool AI ultrasound AI workflows AI-Based Protein Design AI-Powered Test AI-based AI-based drug discovery AI-designed AI-designed drugs AI-designed molecules AI-discovered drugs AI-engineered antibody AI-generated AI-guided AI-native platform AI-powered diagnostics AI-powered drug discovery AI-powered healthcare AI-powered solutions AI-ready AI/ML-enabled product AIM-MASH AIR-001 AJ1 AK006 AK0406 AKAP9 protein AKAP9 protein, human AKT inhibitors AKY-1189 AL ALK Inhibitor ALK7 ALKOVE-1 trial ALPHA3 ALPHA3 trial ALT-positive ALTO-101 ALTO-203 ALX ALX2004 ALZ-801 AMGN AMONDYS AMPA receptor modulator AMPA-PAM AMPLIFY-7P trial AMT-191 AMWC AMX0035 AN2 ANDA ANNE ANOPHTHALMIA AND PULMONARY HYPOPLASIA ANX005 AP3 APG-5918 APG777 APIs APJ APLAS APOE program APOL1-mediated kidney disease AQUILA study AR navigation ARC-EX System ARCT-032 ARD-201 ARG-007 ARIA ARIA risk ARIA-E ARID1A mutation ARO-ALK7 ARO-C3 ARO-INHBE ARO-PNPLA3 ARO-SNCA ARPA-H grant ARROS-1 trial ARTBIO ARTV ASC41 ASCEND trial ASCENT ASCO GI 2026 ASCO preview ASCO-GU ASCO25 ASPIRO trial ASPR ASTX029 ATG-022 ATG-125 ATG-207 ATI ATMP regulation China ATNM-400 ATR ATR/mTOR Inhibitors ATSN-101 ATSN-201 ATTAIN-2 ATX01 AURKA inhibitor AURN001 AVB-114 AVD-104 AVTX AWS HealthLake AXS-14 AZD0120 AZD0780 AZSTARYS Abata AbbVie CEO Abbas Kazimi Abbreviated New Drug Application Abcam Abdominal Fat Abe Bassan Abecma AbelZeta Abeona 's Abetalipoproteinemia Absci Academia (organization) Academy of Pediatrics Accelerate Diagnostics Accord BioPharma Accuray Achieve Life Sciences Acne Vulgaris Acoramidis Acrivon Acrobat Genomics Acromegaly Act of Documentation Actimab-A Actinium Pharmaceuticals Actio Actithera Active Activin E :* * Actuate AcuCort Acute leukemia Adagene Adangme language Adaptive Biotechnologies Adcetris Addictive Behavior Adenosine deaminase deficiency Adenovirus Infections Adherence (attribute) Adherence To Medication Regime Aditum Adjunctive Orthodontic Procedure Adjuvant Melanoma Admilparant Adolescence AdvaMed Diabetes Sector Advanced Imaging Suite Advanced Manufacturing Technology Advanced Melanoma Advanced Therapy Medicinal Products Advanced Urothelial Carcinoma Adverse reaction to drug Advertising (activity) Advisory Board Advita Ortho Aerska Afami-cel Afimetoran Africa Afya Limited Agentic Harmonization Assistant Aggressive Aggressive Periodontitis Agilent Aging Agios Pharmaceuticals Agitation Ahmed ElNawawi AiTEM AilsynBio AimedBio Ainnocence Airna Ajax Health Ajax Therapeutics Ajay Nirula Akeega Akeso 's Alamar Biosciences Alan Ashworth Alarm device Albert Bourla Alberto Lopez Toledo Alchemab Alcohol Use Disorder Alcohol abuse Alcohol or Other Drugs use Aldose Reductase Inhibitor Alejandro Weinstein Alexander Disease Alexei Algen Biotechnologies AlgoTx Alkeus Allakos Allergan Allergy Specialty Allergy to peanuts Allison Candido Allo-Glue platform Allogeneic Allogeneic CD19-OX40-CD3zeta-CAR-mbIL-15-expressing Natural Killer Cells NKX019 Allogeneic CRISPR-edited Anti-CD19 CAR-T Cells CB-010 Allogeneic Human Stem Cell-derived Pancreatic Islet Cells VX-880 Allogeneic bone graft Alloimmune thrombocytopenia Alluminox Alma AlphaDirect technology AlphaFold AlphaMedix Alphabet Altanine Alteogen Alternative Funding Programs Altman Alto Neurosciences Altuviiio Alumni Alva Therapeutics Alveltamig Alyftrek Alzheimer Alzheimer 's agitation Alzheimer 's disease psychosis Alzheimer 's treatment Amar Thyagarajan Amarin Pharma Amazon Health Amazon Pharmacy Amazon Web Services Ambros Therapeutics Ambrosia Ambrosia Biosciences Ambrx American College of Cardiology American Depositary Receipts American Epilepsy Society 2025 AmericasMedicines.com Amethyst Amezosvatein Amgen 's Amgen Uplizna Amgen settlement Amit Singal Amitiza Ammonia level finding Amneal Amolyt Amondys Amphastar Amplify trial Amsterdam facility Amtagvi Amylin Candidate Amyloid-targeting therapy Amylyx AnTenGager Anabolism Analog Analysis of substances Anaphylm Anatol Andembry Andreas Goutopoulos Andreas Wallnöfer Andreessen Horowitz Andrew Grethlein Andrew O Andrew Witty Andy Thomas Ang2 Angela Breton Angelini Industries Angiotensinogen Anima Biotech Animal Health Animal Testing Animal Welfare Animal mane Ankylosing spondylitis Ankyra Therapeutics Ann Arbor Anne Anne Wojcicki Annexon Anniko Annual Reports Anomaly Ventures Ansa Ansa Biotechnologies Anselamimab Ant Afu Ant Group Antares Anthos Anthropological Culture Anti-BTN3A Agonistic Monoclonal Antibody ICT01 Anti-CD19 Monoclonal Antibody Anti-CD36 mAb Anti-CD47 Monoclonal Antibody AK117 Anti-CD52 Monoclonal Antibody ALLO-647 Anti-DR5 Agonistic Monoclonal Antibody INBRX-109 Anti-Inflammatory Agents Anti-Kickback Statute ( Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Anti-OX40 Hexavalent Agonist Antibody INBRX-106 Antibiotic Resistance Antibiotic Resistance, Microbial Antibiotic therapy Antibody Therapeutics Antidepressive Agents Anumana Anything Anzupgo Apheris ADMET Network Apis (invertebrate) Apnea Apogee Therapeutics Apollo robot Appeals court decision Apple Health Applied Pharma Apptronik Apretude Aquestive Therapeutics Aqvesme Araris Arbitrating Arbuckle Arc Bio Arch Biopartners Arch of foot Archimed Architecture Arcturus Arcturus Therapeutics ' Arena BioWorks Areteia Arexvy Arginine Vasopressin-Neurophysin II Preproprotein Argo Biopharma Arikayce ArkBio ArsenalBio Artera Arteriosclerosis Arthritis Arthritis, Psoriatic Arthrosi Artificial (qualifier value) Artificial cardiac pacemaker Artiva Biotherapeutics Asarina Ascenta Capital Ascentage Pharma Ashiq Khan Asia-Pacific Asian Americans Asian Indian AskBio Aspect - Kind of quantity Aspen, Bach Flower Essence Assertio Assertio Holdings Astellas Pharma Astex AstraZeneca 's Astria Astrin Biosciences AstroRx ® Atai Life Sciences Atara 's Atara Biotherapeutics Ataxia Telangiectasia Ataxia, Spinocerebellar Athetoid cerebral palsy Athlone facility Atirmociclib Atropos Health Atsena Attention Attenuated by (contextual qualifier) Atypical Aubrey C. Galloway Audit Committee Chair Augmented Reality Aurion Biotech Autism Spectrum Quotient Autoimmune Alliance Autoimmune Chronic Hepatitis Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F Autolysosome Automated (qualifier value) Autonomous Research Auvelity Avacta Avadel Avadel acquisition Avalo Therapeutics Avantect Avastin Avenzo Average Aves Avicanna Avidity Avobis Bio Awards Awiqli Axial Axplora Axsome Axsome Therapeutics' Ayvakit Azure A³ Strategy B Cell Llama B cell immunomodulator program B-Well trials B-cell Select ™ technology B7-H3-targeted sialidase B7H3/PTK7 bispecific TOP1 BAFF‑R BAG3-associated BATNA BBB BBB shuttle BBI-355 BBI-825 BBOT BCG Vaccine BCG-unresponsive BCL-2 Inhibitor [EPC] BCL11A gene BCL6 gene BCMAxCD19 BCR BDTX-4933 BEAM-302 BEHOLD-1 BEXMAB BHB-1893 BHV-7000 BI BIC/LEN BII BIOSECURE BL-B01D1 - 303 BLA BMB-101 BMB-105 BMN BMRN BMS-986177 BMS-986322 BMS-Hengrui BNT211 BPC 157 BPL BPSI BRCA BRCA2 gene BRENTUXIMAB BROADWAY BROADWAY trial BT-267 BT-409 BTK BTKi BTN3A BW-20829 BX211 BXLS VI Baby KJ Bacterial Infections Baebies Baker Bambusa Therapeutics Bangalore plant Barakat syndrome Barinthus Barrow Neurological Institute Barzolvolimab Basketball game Bassas da India Bausch Health Beat Becker Hewes Becker Muscular Dystrophy Beeline Beginning Behcet Syndrome Belén Belén Garijo Bench International Benedikt von Braunmuehl Bepirovirsen Beqalzi Beqvez BerGenBio merger Berkeley Berkeley Vincent BetterHelp Bettis Bharat BiLockCatcher Bias (Epidemiology) Bicara Therapeutics Bicillin L-A Bicycle Bicycle Health Bicycle Therapeutics Big Data Big Pharma investors Bilirubin Bill Adams Billion Collaboration Billioux Bimzelx Binding action Bintrafusp alfa Bio + Health Bio-Informatics Bio-Techne Bio-Thera BioArctic BioAtla BioCity BioClec BioCryst BioGPU BioPorto BioSpace BioStem BioVU BioVie BioXcel Therapeutics Biochemistry Biocodex Biocon Biologics Bioconjugation Platform Biocytogen Biodexa Bioeconomy Bioepis Biogen CEO Biohaven troriluzole Bioliberty BiomX Biomanufacturing Strategy Biomedicine Biomolecular AI Biopharm Biopharma regulatory issues Biopharma trade war Biopharmaceuticals Biosafety Bioshield Biotech Competition Biotech Fundraising Biotech Layoff Tracker Biotech pipeline shift Biotechnology Advantage Bipartisan Support Bipolar I disorder Bitopertin Bivamelagon Bizengri Blackstone Life Sciences Blackwell Ultra GPU Bladder Risk Blepharitis Blood Blood coagulation tests Bloomington Indiana Blue Owl Healthcare Blueprint Medicines Board Directors Board Resignation Board change Boards (medical device) Bobby Hunter Body Composition Boltz-1 Boltz-2 Bone Density Bone Diseases Boost Boston Pharmaceuticals Boston event Boundless Brain Brain Delivery Module Brain Injuries Brain Research Brain hemorrhage Brain stimulation Brain-Computer Interfaces Brain-Penetrant Drug BrainSpace BrainTransporter platform Brainomix Brainomix 360 Brainshuttle Braveheart Bio Breakthrough Device Designation Breast Acoustic CT Brendan Doran Brenig Therapeutics Brexit impact Breye Therapeutics ' Brian Armstrong Brian Cherry Brian McKelligon Brian Thomas BridGene Briggs Morrison Bright Minds Biosciences Brilaroxazine Brilliance Studies Bristol-Myers Squibb BroADen Phase 1b trial Broad Institute Bruce D. Forrest Bruin-CLL-314 Bruker Corporation Bruton's Tyrosine Kinase Inhibitors [MoA] Bullous pemphigoid Burden BurstDR Business Update Call Bysanti C-CAR031 C-reactive protein C-suite C-suite changes C1QA gene C3 G C3 complement inhibitor C3 glomerulopathy C4 Therapeutics C5 inhibitor CAB CABA-201 CADENCE study CADe/CADx CALD CALR gene CAMP4 CAN10 CAP-002 CAPItello-280 CAPS-5 CAR T-cell CAR-T engineering CAR-iNKT cells CARDINAL study CARsgen Therapeutics CB1 inhibitor CBB-120 CBI-1214 CBX-250 CBX-663 CD CD20 Antigens CD20-directed therapy CD3 T cell CD38 Antigen CD38-directed antibody CD4 + T-cell CD4 + T-cells CD47 Antigen CDC vaccine recommendation CDC7 protein, human CDH17 protein, human CDH6 gene CDK inhibitors CDK2/4 degrader CDK4 inhibitor CDMO/CRO CDMOs CDOO CDTO CE-IVD CEDAR study CELIA CEO Mike CEO Thomas Schinecker CEO Ulf Hannelius CEO appointments CEO replacement CEO resignation CEPI CETP CFD-FOLR1 CHARM Therapeutics CHEK1 protein, human CHORD trial CHRS CHW Access Act CIAS CIDP CAPTIVATE trial CIHR CLD-423 CLIA CLIA-waiver CLL-313 CLL-314 CLUS CMO appointment CMS CMS Interoperability Framework CMT-SORD CNS activity CNS drug development CNS pipeline CNS-3D CNS-penetrant COM503 COM701 COMPOSE trial COO CORALreef Lipids CORALreef trial CORDStrom CPI-refractory tumors CPO CR-001 CRB-701 CRBN gene CREM gene CRISPR CRISPR therapies CRISPR therapy CROI CROSSJECT CROs CRPS-1 CSL-Behring CSNK1E gene CT-132 CT-155 CT-388 CTAD CTMS CTMX CTPS1 inhibitor CTX310 CUE-501 CX-2051 CXCR4 gene CYPRESS study Cabaletta Cabaletta Bio Cabometyx Calcified (qualifier) Caldera Therapeutics Calico Califf California residents Calley Means Calquence Calypso study Cambridge Massachusetts Cambridge research labs Camilla Harder Hartvig Camilla Sylvest Camurus Canadian Cancer Society Canal Row Advisors Cancer Diagnosis Cancer Drug Sales Cancer Prevention Cancer Research Institute Cancer Risk Cancer Survival Candel Cannes Cantargia Cantor Capability Capital Expenditures Capital Markets Capitol Hill Capricor Caps Capsida Biotherapeutics Captain T Cell CarbonAI Carcinoma in Situ CardIQ Cardiac Arrhythmia Cardiac ablation Cardiac care Cardiac monitoring Cardiff University CardioMEMS Hero Cardiospermum grandiflorum Cardiothoracic surgery specialty Carduelis cannabina Caremark Rx Caris MI Carl Dugart Carl June Carlo Incerti Carlos Quezada-Ruiz Carole Ho Caroline Dorsa Cartography Case (situation) CatalYm Catalyst Pharmaceuticals Catherine Bovenizer Celea Therapeutics Celiac Disease Cell Culture Techniques Cell Differentiation process Cell Engineering Cell Shuttle Cell Transplantation Cell-free protein CellDx-Tissue CellOPTIQ Cellares Celldex Cellular Origins Cellular Reprogramming Center for Biologics Evaluation and Research Center for Drug Evaluation and Research Centers for Medicare & Medicaid Services Centers for Medicare and Medicaid Services Central Nervous System Agents Ceperognastat Cerberus Ventures Cerebral Adrenoleukodystrophy Cerebrotendinous Cereno Scientific Chad Chagas Disease Chance Act Changchun GeneScience Pharmaceutical Change Management Charcot-Marie-Tooth Disease Charles Fuchs Charles Ryan Charles Weissmann ChatGPT ChatGPT Health Chaudhuri Chechen language Checkpoint Therapeutics Chemify Chemputation Cheryl Blanchard Cheryl Lubbert Chickenpox Vaccine Chief AI Officer Chief Clinical Officer Chief Development Officer Chief Digital Chief Health Officer Chief Marketing Officer Chief Quality Officer Chief Revenue Officer Chief Science Officer Chief Scientific Officer Chief Strategy Officer Chiesi Group Children Program Chimera organism Chimerix Chimerix acquisition China 's China approval China legal issues resolution China pharma China trial China-Derived Drug China-sourced asset Chinese Neurosurgical Journal Chinese study Cholangiocarcinoma Cholestasis-edema syndrome, Norwegian type Cholesterol Drug Cholinergic Receptors Chondrosarcoma Chordoma Chorea Chorionic Villi Sampling Chris Barry Chris Boerner Chris Lance Chris Shibutani Christiane Bardroff Christopher Martin Christopher Viehbacher Chromatography Chronic Care Management Chronic Condition Chronic Inducible Urticaria Chronic Inflammatory Demyelinating Chronic Obstructive Airway Disease Chronic cough Chronic granulomatous disease Chronic heart failure Chronic lung disease Cigna Cigna 's Ciliary Neurotrophic Factor CinCor Pharma Cingulate Circuit Cirrus Citation Civil Rights Act Clarametyx Biosciences Clarity Claros facility Class Class II Medical Device Classical galactosemia Claude Allary Claudin 18.2 ADC Claudin-18 Isoform A2 ClearNote Health ClearStrand-ASD Clearmind Medicine Clesrovimab CliCr Click Therapeutics ClinVar Clinical Benefit Clinical Decision-Making Clinical Deployment Clinical Equipoise Clinical Evaluations Clinical Relevance Clinical Setback Clinical Trial Suspension Clinical Trial Termination Clinical pharmacology discipline ClinicalTrials.gov CloakLink linker technology Cloning Vectors Closed Loop Medicine Clyde Biosciences Clywedog Therapeutics Co-Diagnostics Co-Dx PCR platform Coartem Cochrane review Coefficient Bio Cognition Therapeutics Cognitive Cognitive function: planning Coherus Oncology Coinbase Coleman Colin Murdoch Collegium Collegium Pharmaceutical Colonic Polyps Colorado Combined immunodeficiency disease Comirnaty Commercial Managed Care - Pharmacy Benefit Manager Commercial Officer Commission approval Committee Communicable Diseases Communication Communications Media Community Clinical Oncology Program Community Health Workers Comorbidity Comparative Genomics Comparison Compass Compassionate Use Compensation Committee Complement Inactivating Agents Complement Membrane Attack Complex Complex Complex Regional Pain Syndromes Compound MOA Compugen Computational Biology Computer Security Concentra Condition Congenital Cytomegalovirus Infection Congenital deafness Congenital disorder of glycosylation type 1A Congenital emphysema Congress reauthorization Congressional Hearings Connect (action) Connecticut biotech Constellation platform Constitutional Challenges Consumer Continuance of life Continuous Delivery Contraceptive Implant Contraceptive methods Contract Development Contrave Controlled release Convenient CorMedix Corbus Pharmaceuticals Corcept Therapeutics' Core CorestemChemon Corneal epithelial defect Corporate Update Correspondence as Topic Corsera Health Corstasis Corvus Corvus Pharmaceuticals Corxel Pharmaceuticals Cosette Pharmaceuticals Cost Control Cost Plus Drugs Cost Savings Cost savings programs Court of Chancery Covalent Interaction Coya Therapeutics CpcPH Craig Crews Cranial Navigation platform Craving for alcohol Create Medicines Creatine Kinase Crescent Biopharma Creyon Criminal Justice Crinetics Crisis Cristal Therapeutics CrossBridge Bio Crossbow Therapeutics Crown Bioscience Cryptigen CryptoMap platform Crystalys Therapeutics Ctexli Cu-Zn Superoxide Dismutase Cues Curapath Cure (remedy) CureVac acquisition Curevo Vaccine Curon Biopharmaceutical Curve Biosciences Cushing 's syndrome Cutaneous sarcoidosis Cyclerion Therapeutics Cyclin-Dependent Kinases Cylinder Health Cynata Cyprium Therapeutics Cyprumed Cytek Biosciences Cytology diagnosis Cytomegalovirus Infections DARPA-funded initiative * * DAWN DAZALS trial DCD gene DCT gene DDX11-AS1 gene DECODE DFO DIA AI Consortium DIAGNODE-3 DLBCL-1 DLL3 DLL3-targeting therapy DMC DMR-001 DNA Methylation DNA Repair DNA Sequence DNA Sequence Rearrangement DNA-damage response DNDi DNL593 DNTH DNTH212 DOGE 's DPP1 inhibitor DREAMM DREAMM-8 DSO DT-101 DT-216P2 DT-9081 DTC DTC Campaign DTX301 DURAVYU DURECT DURGA-1 DXCM DYNAMIKA DYNE-251 Daiichi oncology Damon Lanphear Dana-Farber Danish pharma Danyelza Dark Blue Therapeutics Dark color Darpa DartsBio Darwazah Dasynoc Data Analytics Data Fidelity Data Integrity Data Lakes Data Management Data Release Data Science Data-Driven AI Databricks Datar Cancer Genetics David Guyer David McGuire David Meek David Schenkein Day 2 Daymark Health DePuy Synthes Deal Flow Deal Structure Decanoates Decatur Illinois December 2025 Deciphera acquisition Deep Brain Stimulation Deep Learning DeepMind DeepSearch DeepSeq DeepView System Deerfield Degenerative polyarthritis Degrader-Antibody Conjugates Degree or extent Degrons Del-zota Demand (clinical) Dementia Research Institute Demis Denifanstat Denmark Dennis Dean Dental Solutions Dentatorubral-Pallidoluysian Atrophy Department of Justice Departure - action Depemokimab Deraphan Dermatographic urticaria Dermis Derrick C. Li ; Chief Business Officer Desiccation Desiree Cain Deutsche Bank Develop Developing DeviceGuide Dexcom G7 Dexpramipexole Diabetes Therapy Diabetic Nephropathy Diabetic monitoring - injection sites Diagnostic Accuracy Diamond Therapeutics Diamyd Medical Diastasis Diet, High-Protein Difficult-to-Express Proteins Diffuse Glioma Digital Technology Digital Trial Digital X-ray Digital digestive health Digital innovation Digital therapeutics Dilution technique Dimitri Azar Diorasis Diphosphonates Diphtheria-Tetanus-Pertussis Vaccine Direct-to-Consumer Advertising Directed share Disability Disasters Disc Medicine Disclosure Dispatch Bio Disputes Dizal Dominance Donanemab Dong-E-E-Jiao Donna Haire Dopamine D2 Receptor Dorsal Dose-Limiting Doustdar DoveTree Medicines Dr. Gavin Dawe Dr. Sara Brenner Draig Dren Bio Drug Compounding Drug Development Tool Drug Evaluation, Preclinical Drug Kinetics Drug Negotiation Program Drug Overdose Drug Pricing Program Drug Repositioning Drug development costs Drug licensing Drug packaging industry Dry AMD Dual-chamber systems Duato Duet, Prenatal Multivitamins Dukoral Dupixent-in-a-pill Duvakitug Dyggve-Melchior-Clausen syndrome Dynamic Shared Ownership Dynavax Dyno Therapeutics E-Scopics E. coli disease E100 survey E6(R3 EB613 ECG-AI ECLIPSE program ECT EDIT-401 EDNRA gene EKF Diagnostics ELEVATE-44 ELP Technology ELSC ELT ELV001 ELVN EMA Approval EMBARK EMBER-3 trial EMPEROR EMPEROR Phase III trial ENCELTO ENT1 ENV-294 ENaBL Platform EO-1022 EO-3021 EOC EOS-215 EOS-984 EP'949 EP4 Antagonist ONO-4578 EP4 antagonist EP4 receptor antagonist EPCAM gene EPCORE EPI-321 EPKINLY EPRAD ER-100 ER-Positive HER2-Negative Breast Cancer ERAS-0015 ES-SCLC ESC25 ESGO ESK-001 ESMO IO ESO-T01 ESSDAI ETA EU AI Act health EU Approval EUA EVO301 EVO756 EVOKE trial EVOQ EXCALIBER-RRMM EXHALE-4 EY Early Intervention (Education) Early-Stage Pipeline East Asian American East Asian Americans East Windsor facility Ebglyss Ecnoglutide Economic Conditions Economic Growth Economic Investment Committee Edap Edenbridge Edge AI Edgewise Therapeutics Edison Oncology Edison Scientific Editas Medicine Education, Medical Edward Conner Efruxifermin Eftilagimod alfa Eight Ekterly Elasticity Imaging Techniques Election Proposal Electrocardiogram Electrocardiography, 12-Lead Electroconvulsive Therapy Electroencephalography Electromechanical dissociation Electronic Electronic Health Records Electroporation Eledon Elektrofi ElevAAte Elevara Medicines Eli Lilly ; Novo Nordisk Eli Lilly acquisition Eli Lilly competition Elicio Therapeutics Elinzanetant Elix Elizabeth Montgomery Elkridge facility Ella Platform Eloralintide Elraglusib Elrexfio Elsa Emblaveo Emergency Situation Emergency Use Authorization Emergency department patient visit Emergent BioSolutions Emi-Le Emirati Genome Program Employer Empower Pharmacy Empowered Empress Emrelis Enanta Enbrel Enbumyst Encapsulated (qualifier value) Encephalitis Encephalitis, St. Louis Encephalopathies Encryption End Point Endogenous Eneboparatide England Enh3ance trial Enhance (action) Enki generative AI Enlaza Enrollment Entera Bio Enterprise Entity Entrada Therapeutics ' Entyvio Environmental pool Enzeevu Enzyme Replacement Therapy Enzyme Therapy EpiVax Epicrispr Epidemic Epidemic Preparedness Innovations Epigenic Epilepsies, Partial Epiminder Epitopea Equillium Equipment and supply inventories Erelzi Erica Palsis Erica Taylor Erik Atkisson Erika Porcelli Erythrocytes Erythropoietic Protoporphyria Escalation Eshkenazi EsoBiotec Esophageal Neoplasms Essential Tremor Esthetics (discipline) Estimated Estrogen receptor positive Ethics Ethics Committees Etiome Eua (gastropod) Eucalyptus Eukaryotic Cells Europe market European Group for Blood and Marrow Transplantation risk score (assessment scale) European Hematology Association European Hematology Association ( European Medicines Agency Evaluate report Evan Rachlin Evfraxy Evommune Evopoint Biosciences Evorpacept Evrysdi Ewings sarcoma Ex-FDA ExPEC9V Exact brand biomedical or dental material Excalipoint Therapeutics Excellergy Exciva Executive Board Executive Board Changes Executive Leadership Team Executive Order 14273 Executive Team Change Executive Vice President Exercise Exit activity Exl-111 Exon Skipping Exons Expanding Expedition Medicines Experience Experimental drug Expert Systems Expiration Exposome Extencilline External Director External Ventricular Drain Eye Drops Eye safety EyePoint EyePoint Pharmaceuticals Eyebrow structure Eyelash Eylea biosimilar FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY 1 FAERS FAK/ALK/ROS1 Inhibitor APG-2449 FALKON FDA-approved therapies FDA-cleared AI FDA/EMA regulatory pathways FILSPARI FINDER FINEARTS-HF FL-501 FOG-001 FORTE FORTITUDE-101 FORTITUDE-102 FOXD3 gene FREEDOM2 FSP FUJIFILM Biotechnologies FUROSCIX FXR314 FXS6837 FY2026 Facilities Association Facioscapulohumeral Factor XI Factor XI antibody Factor XIa inhibitor Factory Faeth Family Fringillidae (organism) Family suidae Fanconi Anemia Farapulse Faro Faron Pharmaceuticals Fasenra Faslodex Favored Favored Nation Fear (Mental Process) Febrile Convulsions Federal Appeals Court Federal reduction-in-force statute Federated AI Feeling content Fees Fellows Ferring Ferring Pharmaceuticals Fertility Fetal Hemoglobin Fetal and neonatal alloimmune thrombocytopenia Fetroja Fetus FibroBiologics FibroGen 's Fibroblast Therapy Fibromatosis Fibrosis Fibrosis, Liver Field Medical Fill/finish Filspari Finance Financial Stress Financial Times Findable Fine - adjective First-in-Human Clinical Trial First-in-Human Study Fiscal 2026 Flare platform Flatiron Health Flexible Flow Flow Cytometry FlowMod Flu A/B FluBlok FluidCrystal technology FluoGuide Fluzone Focal glomerulosclerosis FogPharma Food Allergy Food Policy Food, Processed For which was done Forced Vital Capacity Forma buyout Formation Bio Formula - diet Fortrea Foundations Fractyl Health Francis Francis Braun Francis Wilson Frankfurt plant closure Frazier Life Sciences Free Mind ' Campaign Free Nurse Program ' FreeStyle Libre Fresenius Freshworks Friedreich Ataxia Fujifilm Biotechnologies Full-Life Functional improvement Fund I Fund III Fused structure Futility Analysis Future FutureTech II G12C inhibitors G12D inhibitor G3BP2 gene GABA A GABAergic interneurons GALA peptide GB-0895 GBS GCG GCG/GLP-1 agonist GDF8 protein, human GDUFA IV GE8820 GEMINI trial GEN1107 GH Research GH001 GI care GI oncology GLA GLM101 GLOW2 GLP-1 medications GLP-1 pipeline GLP-1 therapies GLP-1/GIP agonist GLP-1/GIP co-agonist GLP-1/GIP therapies GLP-1/GLP-2 GLP-1/glucagon GLP-1RA GLPG5101 GM-2505 GMMA platform GMP GMP violations GO29781 GPC3 protein, human GPCR pipeline GPCRs GPR182 gene GRADUAL-3 GRAS Reform GRT-001 GS-0321 GS-098 GS/pan-Notch Inhibitor AL101 GSBR-1290 GSK 's GT801 GTPase-Activating Proteins GUB014295 GUBamy GUTC GXO Gabriel Baertschi GalNAc Galafold Galapagos layoffs Galatea Bio Galaxies Galaxy Brain Scientific Galderma Galecto Galera Therapeutics Galleri Galleri test Galux Gambling Gamma/Delta T-Lymphocyte Gan & Lee Pharmaceuticals Garda Therapeutics Gardasil sales Garetosmab Garijo Gastric Bypass Gastrointestinal Neoplasms Gastroparesis Gate Bioscience Gateway Labs Gaucher Disease Gavi Vaccine Gdańsk Gefion AI Supercomputer Gefurulimab GemPharmatech Gemini Enterprise GenEvolutioN GenSci Gene Expression Profiling Gene Writing Gene-Edited Genelux Corporation General Data Protection Regulation Generalized pustular psoriasis Generate Generation Park Generations Generative Phosphoproteomics Genes Genetic Biomarkers Genetic Leap Genetic screening method Genetic testing for cancer risk Genetix Biotherapeutics Genevant Geno J. Germano Genomenon Genomic Orientation Genotype Genus Aviceda Genus Malus Genus: Coronavirus GeoVax Geoff Hamilton ; Chief Financial Officer Geographic Intersection Geographic Locations German language Geron Geron Corporation Gestures Giant Cell Arteritis Giant Cell Tumors Gilgamesh Gitte Pugholm Aabo Glenmark Glenn Coleman Glickman Glioma Global Biobank Global Health Global Restructuring Global commercial operations Globalization Glucagon-Like Peptide 2 GlycoEra Glycomine Good Machine Learning Practice Google Gordon Gossamer Bio Gossypium Gout Gout Suppressants GovEvents Government Shutdown Grabody-B Grace Niu Gram-negative infections GramEye Grand Prix Graphene Gray Delany Great Healthcare Plan Greater China Region Gregory Verdine Grin Gross (qualifier value) Gross margin Growth Differentiation Factor 15 Grünenthal Guardant Health Gubra Ventures Guidance 2024 Guillain-Barre Syndrome Guillain-Barré syndrome Gumokimab Gurunathan Gut-Brain Health GxP Gyre stock H. Martin Seidel , H2H trial H5 avian influenza H5 bird flu HCM HCP HDV RNA HER2- HER2-low HER2-low breast cancer HER2-positive HER2-positive metastatic breast cancer HER2-targeted therapy HER2-targeting antibody drug conjugate HER2-ultralow HER2CLIMB-05 HER3 HERCULES trial HERO trial HFmrEF HH160 HHS Overhaul HIF-2a HIV franchise HKEX HLX316 HLX701 HNGE HOOKIPA HOPE-2 trial HPP HR+ HR-positive/HER2-negative breast cancer HRR gene mutation HRS-9821 HS-001 HS-20094 HS-20110 HSCT HSE HSP90 Heat-Shock Proteins HSV-1 viral vector HTGS26 HTS HU6 Haduvio Hahn Hair Analysis Hairy Cell Leukemia Haisco Haleon demerger Halle Halo brace Halozyme Therapeutics Hamed Khalili Hand Strength Hans Henrik Chrois Christensen Hansoh Hansoh Pharma Hansoh Pharmaceutical Hansoh Pharmaceuticals Hantavirus Harbinger Harbour Mice technology Harbour Mice ® technology Harmony Biosciences Harout Harris Lazarre Harvard Research Harvard University Hassabis Hatteras Hatteras Opportunity Fund I Hatteras Venture Fund VII Haya Hazard Ratio HeFH Head of Growth Head of Non-Clinical Development Head of Strategy Health & Wellness Health Care Sector Health Care Systems Health Data Innovations Health Data Research Service Health Data Research UK Health Equity Health Improvement Health Information Systems Health Insurance Portability and Accountability Act Health Services Research Health Services, National Health Workforce Health conditions:-:Point in time:^Patient:- HealthCare Royalty Healthcare Payers Healthy America Hearing Heather Knight Helen Jones Helicore Helix (Snails) Hematology (discipline) Hemgenix Hemlibra Hemophagocytic Hemophilia B Henlius Hepatitis D Infection Hepatitis, Alcoholic Hepatoscope Hereditary Hereditary Diffuse Leukoencephalopathy with Spheroids Hereditary pancreatitis Hermanski-Pudlak Syndrome Hernexeos Herpes NOS Herpes Simplex Infections Hers Heterogeneity Heterotopic Ossification Hickory trial Hidradenitis High Drop-Out Rate High dose High-Frequency Microsatellite Instability Highest Hikal HilleVax Hillhouse Capital Hinge Health Hiroyuki Sonoda HistoSonics exit Histone deacetylase inhibitor Histopathological aspects Hizentra Hoist device Holistic epilepsy management Holter Electrocardiography Home Use Honeymoon Effect Hong Hong Kong IPO Hongjiang Miao Hookipa Pharma Horizon Hormone replacement therapy Hospital admission Hospital specialist Hospitals Hour House Appropriations Committee Houston Huahui Health Human Factors Human Glandular Kallikrein 2 Human Services Secretary Humanitarian Exemptions Humira patent expiration Hungary Huntington Disease Hyaluronic Acid anchoring platform Hybrid AI Hybrid Care Model Hypercon Hyperinsulinism Hypertrophic cardiomyopathy without obstruction Hypocupremia Hypoglycemia Hypophosphatasia Hypothalamic structure Høiland I CAN trial IBC IBI343 IBI363 IBTROZI ICER ICU ICU bedside procedures ICU nursing shortages IDE034 IDEAYA IDEAYA Biosciences IDO1 IDS gene IDWeek IDeate-Lung01 IGC IGF-1R Antisense Oligodeoxynucleotide-treated Autologous Glioma Cells IGV-001 IGF1R gene IGYNTE IHC II IL-13 antibody IL-17A monoclonal antibody IL-2 pathway IL-22 antibody IL-23 receptor antagonist IL-31 receptor alpha IL13 gene IL1RAP antibodies IL1RAP protein, human IMC002 IMM2510/AXN-2510 IMNN-101 IMPACT trial IMVT IMforte trial IMvigor011 INAVO120 INBRAIN INBRX-101 IND-enabling studies INF904 INHBE INHBE gene INLIGHT INLIGHT trial INMB INNOVOTEX INOVIO INZ-701 INmune Bio IO Biotech IPG IPS test IQLIK IQVIA IRAK3 gene IRAK4 gene ISAC ISB ISM-001 ISM4808 ITK gene Iambic Iban language Icebergs Ichnos Glenmark Identification (Psychology) Idvynso IgG4-RD IgG4-related disease IgM antibodies Igalmi IkT-001Pro Illinois (geographic location) Illumina Ventures ImCheck Therapeutics Image Analysis Group Imagio Imaging System Imlunestrant Immune Activation Immunic ImmunoForge ImmunoPrecise Antibodies Immunoassay method Immunocompromised Host Immunofoco Immunoglobulin M Immunoglobulins Immunologic Adjuvants Immunopharma Immutep Impacts, Environmental Improved Improving (qualifier value) Imsidolimab Imunon Imvax In Vitro [Publication Type] Inavolisib Incentives Incheon Inclusion Incubated India 's Indiana Indiana manufacturing Indianapolis Indication restriction Individualized Indivior Infant, Newborn Infectious Canine Hepatitis Inference Infinity Bio Infinity Smart platform InflaRx Ingram Inhalation Solution Inhaler Inhibikase Inhibikase Therapeutics Inhibitor Discovery Initiative Injury of cornea Inluriyo InnoCare Innovative Health Initiative Innovative Medicine Innovent Innoviva Inovio Pharmaceuticals Inozyme Inspira Technologies Instill - dosing instruction imperative Instrument - device Insurance Premiums Intas Intellidrop Intent Biologics Intercept Pharmaceuticals Interdisciplinary Studies Interim report Interius BioTherapeutics Interleukin-2 Interleukin-23 Subunit p19 International International Aspects International Drug Prices Interoperability Interoperable Interventional Urology Interventional procedure Interventional radiology Intervertebral Disc Degeneration Interview Intestinal Failure IntraBio IntraBio Ltd. Intranasal approach Intravascular Invest Europe Investigational New Drugs Invivyd Ionis Iovance Biotherapeutics Iptacopan Ireland Irish healthcare Ironwood IsoDDE IsomAb Israeli (population group) Itovebi Itvisma Ivory Ixchiq vaccine Ixiaro Ixo-vec Izervay JADE101 JAGX JAK/SYK inhibitor JAK1/TYK2 inhibitor JAM JAMA study JBIO JC Virus JCV JN.1-lineage JNJ JNJ-2113 JNJ-4804 JPM Healthcare Conference JPMHC JPY JS005 JSPR JUST-AAV Jack Phillips Jacobio Pharma Jacqueline Corrigan-Curay Jade Biosciences Jaguar Gene Therapy Jaguar Health Jake Leach James Jamie Jamila Jan Hillson Janssen Janssen Vaccines January 2026 Janus kinase 1 Janus kinase 2 Janus kinase inhibitor Januvia Jascayd Jason Litten Jasper Therapeutics Jeavons syndrome Jeff Knight Jefferies Jeffrey Venstrom Jeito Jeito Capital Jeito II Jeremy Shefner Jerome Jersey pharma Jersey site Jesper Jian Jiangsu Hengrui Jigani Facility Jim Lang Jim O'Neill Jiwan Joaquin Job Development Jodi Ungrodt Joe Rogan Joe Willey John Carroll Johnson & Johnson Intra-Cellular Joint Atomic Model Joint Ventures Jonathan Arambula Jonathan Vigdorchik Jonmark Jorge Bartolome Julie Kim Juncos June Junshi Juvenile K Pro KARDIA-3 KARDINAL trial KAT5 wt Allele KAT6A degrader KB801 KCNT1 gene KER-0193 KEYNOTE-671 KEYNOTE-689 trial KEYNOTE-B96 KEYNOTE-B96 trial KINECT-DCP KIR-CAR KIT KKR KMT2A gene KOMET-017 KP.2 strain KPI-012 KRAS KRAS NP_004976.2:p.G12C KRAS inhibitor KRAS-mutant cancers Kaerus KaiSR Kainova Therapeutics Kakao Healthcare Kaken Kala Bio Kane Biotech Kankakee Illinois Kaposi 's sarcoma Kappa-Opioid Receptor Kardigan Karen Massey Karen Smith Karin Conde-Knape Kashiv BioSciences Kate Estep Kate Walsh Keir Starmer Keith Keith Vendola Kelun-Biotech Ken Paxton Ken Song Kendall Square Kennedy 's Kenneth W. O’Keefe Keren Leshem Kerry Dailey Kestrel Kevin Hardage Kevin Lobo Keystone Symposia Keytruda Qlex Keytruda SC Keytruda bladder cancer Keytruda head-to-head trial Keytruda patent Khalid Nabilsi Kidney Kidney Failure Kidney Failure, Acute Kidney Failure, Chronic Kim Kin-Hung Peony Yu Kinase Assay Kits Kinaset Kinevant Kissei Kit device Kite Pharma partnership Kite, device (physical object) Klaas Zuideveld Kleiner Knee pain Kodiak Sciences Komodo Health Kong Korean language Kosmos Kostaive Kowa Krazati Kristin Bittenbender Kriya Kronos Kronos Bio Krystal Biotech Kumquat Biosciences Kura Oncology Kv7 activator Kyle LaHucik Kymab Kymera Therapeutics Kyverna Therapeutics LAG-3 immunotherapy LAVA-1266 LBCL LBP LDLR gene LEAD platform LEAP District LEAP2MONO LENZ LFMD LGBTQ+ professionals LIGAND-AI LLM-based technology LMT15 LONP1 gene LOTIS-7 LP.8.1 sublineage LRP4 gene LRPAP1 gene LTBR agonist LUCE-1 LUNA 3 trial LX9851 LYT 100 LaNova Medicines Labor (Childbirth) Labor Unions Lancet Landscapes Languages Larix Lark Health LarkVantage Lars Rebien Sørensen Larsucosterol Latex Fixation Tests Latigo Latozinemab Launch-HTN Lawrenceville Leaked Lean Derisking Leapfrog Bio Lebanon Leber congenital amaurosis-4 Leerink Partners Legal Case Legal Challenges Lehigh Valley Lens platform LensAI Lenvima Lepodisiran Lesion Lesion reduction Letitia James Leukoencephalopathy, Progressive Multifocal Lewy bodies Libertas Bio Libertyville Illinois License Agreement Life Life Biosciences LifeMine LifeSignals Lifespan Extension Lifetech Lifyorli Ligand Pharmaceuticals Light AI Ligufalimab Lilly 's Lilly partnership Limitation Limited (extensiveness) Limited stage (cancer stage) Linac QA LinusBio Lionel Seltz Lipid Metabolism Disorders Lipids Lipoidosis Lipoprotein(a ) Lisa Eli Litespark Lithotripsy Livdelzi Live - Specimen Condition Live Biotherapeutic Product Liver damage Loan Localized Logica London Bioscience Innovation Centre London Cancer Long-Term Strategy Longwood Fund Lorbrena Lorundrostat Losers Lotte Lower Profile Lower Rates Lp(a ) drug Lukas Braunschweiler Lukácsháza Luma Health Lumakras Lumina 3D Lumryz LunAIRo Lung Diseases, Interstitial Lung consolidation Lung-201 Lunit Lunit AI Lunit SCOPE Lunsekimig Lunsumio Lupus treatment Lutathera Lutetium-177 Lyell Immunopharma Lyfgenia Lymphatic Abnormalities Lymphocyte Count measurement Lymphocytes Lymphocytes, Tumor-Infiltrating Lymphodepletion Therapy Lymphohistiocytosis Lynavoy Lynk Lynozyfic Lyophilized Inactivated Group A Streptococcus TARA-002 Lysosomal Storage Diseases M financing M growth fund M&A consolidation M&A surge M&A transactions M-TEER M.D. M6495 M9466 MACE-3 MADRS score MAGNITUDE-2 MASLD MC4R MCED MDASE MDD MDM2 Antagonist ASTX295 MDNA11 MDNA113 MDR CE Mark MEERKAT trial MESA MET exon 14 skipping mutation MET protein MIBC MIPSA technology MIRACLE trial MIT MITIGATE trial MMRV vaccine MOG antibody disease MR closure MR-139 MRD MRM Health MS MSH5 gene MST brand of morphine sulfate MST-0312 MTLE MTX240 MWT MYO7A gene MZE829 MaGic trial MacTel Machado-Joseph Disease Machine Macular degeneration Macular retinal edema Madness Madrigal Magnet <device> Magnetic Seizure Therapy MagnetisMM-5 Magnetocardiography Mahery Maintenance study Major Depressive Disorder Maker (occupation) Malignant Bone Neoplasm Malignant Female Reproductive System Neoplasm Malignant neoplasm of cardioesophageal junction of stomach Malignant neoplasm of thyroid Malus domestica Management procedure Manfidokimab Manifold Bio Manihot esculenta MannKind Mantelli Manufactured Supplies Manufacturer Manufacturing costs Marcel Reichen Marco Rubio Marengo Maria C. Freire Marietta Pennsylvania Marjan Farid Mark McLellan Mark Pavao Mark Stevenson Mark Turco Markers (device) Martes pennanti Martin Martin Makary Mary-Elizabeth MassBio Massachusetts biotech Massive Mastermind Platform Mastocytosis, Systemic Matchpoint Therapeutics Maternal Health Matt Buckham Matt Skelton May 18 Mayne Mayo Clinic Mazdutide Measurement Measuring ruler, device Mechanism (attribute) MedSurg MediKarma MediView MediView XR MediView XR90 Median Technologies Medicaid block grants Medicaid fraud Medical Advisory Board Medical Affairs Medical Communications Medical Imaging Medical Records Medical pathologist Medicare coverage Medicare drug prices Medicare fraud Medicare reforms Medicenna Medicines Australia Medicus Pharma MedisourceRx Medivis Medtronic Megadeals Megarounds Meister Melanie Ivarsson Melanoma TRP2 CTL Epitope Vaccine SCIB1 Membranous glomerulonephritis MenABCWY Menopausal symptom Menstruation Mental association Mentorships Merck 's Merck Verona Mereo BioPharma Mersana Metagenomi Metals Metapneumovirus Metastasis from malignant neoplasm of colon and/or rectum Metastatic Pancreatic Ductal Adenocarcinoma Metastatic Prostate Carcinoma Metastatic to Metis people Metric (substance) Michael Bierl Michael Burgess Michael Chou Michael Houghton Michael Kott Michael Langer Michael Rogers Microarray Analysis Microbial Microbiome SER-155 Microbiome therapeutics Micron Biomedical Microsoft Discovery Microsoft Teams Microvillus inclusion disease Mikael Mikael Dolsten Mikaela Naylon Give Kids a Mike Hershkovitz Mike Sciandra Mike Stuart Mild cognitive disorder Miltenyi Biopharma MindWalk Holdings Corp. Minder system Mindpeak MinervaX MingMed Biotechnology Minghui Minimal Residual Disease Negativity Ministry of Health Minxiang Zeng Mirum Mirum Pharmaceuticals Misleading Drug Ads Missing Mitchel Berger Mitigation Strategy Mitochondrial Diseases Mitral valvuloplasty Mitsubishi Mitsubishi Tanabe Pharma MoSEIC Mobile Health Mochida Pharmaceutical Modernization Modeyso Modic Mohammed Moist Molecular Clamp technology Molecular Gates Molecular Imaging Molecular Targets Moleculin Monarez Monte Montes Montgomery County Montgomery-Åsberg Depression Rating Scale Month of May MoonLake Immunotherapeutics Morbidity - disease rate Morgan Stanley Morristown Mourenx Movantik Move GBS Forward™ Movement Mucopolysaccharidosis I Mucopolysaccharidosis III Multiomics Mumps Mundipharma Munich Regional Court Mural Mural Oncology Muscarinic Agonists Muscle Tissue Muscle strain Muscle-Boosting Drugs Musk MyOme MyPhenome Mycobacterium tuberculosis Myelin Sheath Myeloid Progenitor Cells Myocardial Infarction Myositis N-methyl-N-2-(methylsulfinyl)ethylpropionic acid amide NAION NALF2 gene NBI-1070770 NDA filing NEFL gene NEO100 NEPTUNUS-1 NEPTUNUS-2 NGAL NGM NGN-401 NGS NHS NHS England NHS trial NHS-Galleri trial NIH grant NIH layoffs NIH-funded NINL gene NK1/NK3 receptors NKTX NLRP3 inhibitor NON Mouse NOVI NP-MP1 NPDR NPM1 gene NPM1-mutant NR1H4 gene NR4A2 gene NRG NRG1 gene NRTX-1001 NSCEB NTHI NUCLIDIUM NUSAP1 gene NUZ-001 NVG-291 NVIDIA 's NVIDIA Lilly NX-3911 Nabla Bio Nach01 Namandjé Bumpus NanoDisc NanoPhoria Nanobody Discovery Platform Nanostructured Materials Naphthoquinones Nasal Polyps Nasal drug delivery Nasal inflammation Nasdaq Stockholm Nasua Natalia Misciattelli Natera National Association of National Biotechnology Conference National Cancer Institute National Resilience National Security Commission Natural killer triggering receptor, human Nature Aging Nav1.8 inhibitors NeOnc Technologies Nebulizers Negative Predictive Value of Diagnostic Test Negotiation Program Neko Health Nektar Nelson Sun ; Chief Operating Officer Nemluvio Nemvaleukin Alfa Neo-1 Neoantigen Neomorph NeuraClick Neural Circuit Stimulation Neural Network Simulation NeuralPLexer Neurimmune Neuro Disease Neurogene Neuromyelitis Optica Neurona Therapeutics Neuropsychology Neurosteroids Neurostimulation procedures of spinal cord tissue Neurotrophic keratitis Nevada Nevada <Geographic Area> New Approach New Approach Methodologies New Jersey operations New York AG New York Stock Exchange New-onset refractory status epilepticus NewAmsterdam NewBridge Pharmaceuticals NewLimit Newborn NewcelX Nexon platform Nexplanon Next Pathways NextCure NextGen NextRNA Nextstellis NiKang Therapeutics Nia Tatsis Nick Eshkenazi Nick Vatakis Nicole Ossey Nicole Verdun Nimacimab Nimbus Nipocalimab Nippon Shinyaku Nominee Non-Hormonal Non-Incretin Non-Muscle Non-Opioid Non-Opioid Pain Nona Biosciences Nonalcoholic Steatohepatitis Noninvasive Endpoint Noom Nordisk alliance Nordisk facility North Chicago North Chicago Illinois North Star Ambulatory Assessment Clinical Classification Nosis Novartis Venture Fund Novartis-Chinook acquisition November 2025 Novo Holdings NovoCare Nubeqa Nucleus RadioPharma Nulibry Numab Nutrition Guidelines Nuvation Nuvation Bio Nuzolvence OBT OBX-115 OCT50 OCU400 OCU410 OFA OHSU OIG bulletin OKYO OLN324 OM336 OMass ONS-5010 ONWARD OPKO OPTIMA trial ORKA-001 ORN-252 ORNITHINE CARBAMOYLTRANSFERASE ORX142 ORX489 OSE Immunotherapeutics OTX-201 OTX-TKI OX2R agonists OX40 agonist OX40 receptor OXPHOS pathway OXTR gene Oberon Obesity Drugs Obesity Trial Obesity care Obsidian Therapeutics Obstructed Ocaliva Occupational activity of managing finances Oceanside Ocedurenone Ocrevus October Ocugen Ocular Therapeutix OdyssION platform Office Officer David Rose Offit Ogilvy Health Ohtuvayre Ollin Ollin Biosciences Omeros Corporation Omicron Omicron JN.1 Omnipod Omniverse On-Demand Events On-Demand Webinars Onapgo Once-Weekly Insulin Oncoinvent ASA Oncologic Drugs Advisory Committee Oncology Collaboration Oncology Focus Oncolytic Viruses OpenFold Consortium Operating Operating expenses Operational streamlining Opfolda Ophthalmological implant Opiate Addiction Opioid Opioid Crisis Opioid Use Disorder Opportunity Fund III Opthea Opthea 's Opthea layoffs Optigo Biotherapeutics OptimiZe technology Optimism Optinose Optogenetic Gene Therapy Opvee divestiture Oracle Health Oral Medication Oral Medicine Oral Wegovy Oral region Orals Orano Orbital Therapeutics Orca-T. Order Tubulidentata (organism) Organ Shortage Organisation for Economic Co-Operation and Development Organovo Ori-C101 Oricell Therapeutics Orion Group Orionis Biosciences Orna Therapeutics Orotecan Orphan Cures Act Oruka Orum Therapeutics Oryon Cell Therapies Oslo Stock Exchange Osteogenesis Imperfecta Osteoporosis Ostro acquisition Otsuka 's Otsuka Holdings Otsuka Pharmaceutical Ottava Oura Ring Outfront Health Outlook Therapeutics ' Outsourcing Ovation.io Overweight Owkin Ownership Oxervate Oxford BioTherapeutics Oxford Finance Oxford spinout Oxycontin Oyster Point P-Value PADOVA study PALSONIFY PB212 PBA PBC PBMs PC Platform PCED PCSK9 protein, human PCVs PD-1xVEGF bispecific PD-L1xVEGF-A PDE3/4 inhibitor PDE4 inhibitor PDUFA VIII PER-001 PERIDOT PERSEUS trial PET/CT scan PF-06954522 PF-08653944 PF-ILDs PFAS gene PGI PGN-EDODM1 PHD inhibitor PI3 K inhibitors PI3 K pathway PIK3CA gene PIK3CA mutation PIK3CA-driven PIK3CA-mutant PIK3CA/AKT1/PTEN pathway PIKTOR PIPE financing PIVOT-PO trial PKMYT1 protein, human PKP2-associated cardiomyopathy PMN310 POETYK PP353 PPF PRECISE-AD trial PREVAIL trial PRISM BioLab PROBODY PROGRESS-AD PROSERA PROTACs PRT13722 PRV PRX012 PSMA PSMA-targeting PTAB PTEN-deficient tumors PTH1R gene PTK7 PTK7 protein, human PTRS PURPOSE studies PYNNACLE trial Pacira Pacira BioSciences Pain Palleon Palvella Therapeutics Palynziq Pancreatitis, Acute Pandion Paolo Tarantino Papillary Disease Paratek Parker Institute for Cancer Immunotherapy Parkinson 's Paroxysmal nocturnal hemoglobinuria Part B drugs Participant Partner Therapeutics Partnering Partnering Office Pasadena Path-IO Patient Protection and Affordable Care Act Patient data Patient location type - Department Patient-Centered Patrick Vink Patrizia Cavazzoni Patterns Paul Edick Paul Fornazzari Paul McKenzie Paul Thomas Pavblu Payer Engagement Payspan Pazdur Pediatrics Pedro Beltran Peer-Reviewed Research Pelage Pelage Pharmaceuticals Pemgarda Pemphigus Vulgaris Pennsylvania site closure PepGen PepMetics Perception Perianal fistula Peripheral Arterial Diseases Peripheral neuropathic pain Peripheral neuropathy due to and following antineoplastic therapy Perjeta Perkins Permanent Peroxisome Proliferator-Activated Receptors Persica Persistent Personality Character Perspective Perturb-seq Pet Animal Peter Greenleaf Peyronie 's disease Pfizer 's Pfizer Astellas Padcev Pfizer Ventures Pfizer acquisition Pfizer staff Pfizer vet Pfizer-BioNTech Phagocytosis Pharma Acquisition Pharma Concessions Pharma Manufacturing Pharma Tariffs Pharma import taxes Pharmaceutical Group Pharmaceutical Ingredients Reserve Pharmaceutical Layoffs Pharmaceutical Packaging Pharmaceutical Policy Pharmaceutical executive pay Pharmacogenomics Pharmatech Phase 1 - 2a Phase 1 Data Phase 1b/2 Trial Phase 1b/2a Phase 2 BEACON Phase 2 Failure Phase 2 HORIZON Phase 2 VALIANT Phase 2 data Phase 2 results Phase 2 termination Phase 2a Phase 2a Trial Phase 2b SYMMETRY Phase 2b trial Phase 3 Breast Cancer Trial Phase 3 COMPETE trial Phase 3 CREST trial Phase 3 HAELO Phase 3 INDIGO Phase 3 INDIGO trial Phase 3 PIVOT-PO trial Phase 3 RINGSIDE trial Phase 3 SENTRY trial Phase 3 planning Phase 3 plans Phase 3 prospects Phase 3 readiness Phase I – III study Phase II Failure Phase II data Phase III AURORA trial Phase III Essence study Phase III MAGNITUDE trial Phase III MARIPOSA trial Phase III REGENCY trial Phase III ReSPECT trial Phase III ZENITH trial Phase IIa Phenylketonurias Phesi Philip Brainin Phoenix Arizona Photoimmunotherapy Physical AI Physical Examination Physical activity Physician Executives PiNACLE Piclidenoson Pilatus Pill Penalty Pinnacle Medicines Pioneer Antibody Discovery Pioneering Medicines Pipeline Review Pipeline Strategy Piperine Extract (Standardized) Pitch - substance Pivotal Pivotal Trial Plants Plaque (lesion) Plasma Plenary Speakers Plexiform Neurofibroma Pliability Plozasiran Pluri Poisons Pol Theta Polaryx Therapeutics Polpharma Biologics Polycythemia Polyradiculoneuropathy Polyradiculoneuropathy, Chronic Inflammatory Demyelinating Pombiliti + Pooled Sample Portfolio diversification Positive Post-Pandemic Downsizing Post-bankruptcy consolidation Post-marketing study Poster Practice Experience Prasad 's Prasinezumab Pre-Clinical Model Pre-Consult Precision Pre-Exposure Prophylaxis Pre-filled Syringe Prealbumin Precision Diagnostics Precision Imaging Network PrecisionLife Predict Pregnanolone Prelude Therapeutics Premier Inc. Prescription Drug Overuse Prescription procedure Presidential Symposium Preventive Health Programs Previous Primary Primary hyperoxaluria Primary sclerosing cholangitis Priority Review Voucher Private Room Private financing Privigen ProFound Therapeutics ProMIS Neurosciences Proactive Health Probiotics Problem Probody Platform Professional guide Profluent Progestins Projections Promotional Claims Prompts Prophylactic treatment Protara Therapeutics Protection Protein Domain Protein Kinase C Protein Kinase C Inhibitor Protein Purification Protein, Organized by Structure Protein-Protein Interaction Proto-Oncogene Proteins c-akt Protoporphyrin IX Provider Provider Services Proximity Prurigo Pruritus PsA-2 trial PsCatCh2.0 Pseudobulbar affect PsiThera Psoriatic PsyLabs Psyence BioMed Public Health Trust Public Listing Puerto Rico Pulmonary Eosinophilia Pulmonary artery pressure Pulmonary veins Purchase Purchased Services, Clinical and Biomedical, Calibration, Laboratory Purchased Services, Clinical and Biomedical, Research Purchased Services, Staffing, Supply Chain Purdue PureTech Purpura, Thrombotic Thrombocytopenic Pushechnikov Put Option Agreement Pyoderma Gangrenosum Pyzchiva Q-Scientist Q1 trends Q126 Q2 layoff Q2 sales Q4 FY2025 QA QA102 QIAsymphony QLS-111 QRS prolongation QT Imaging QUC398 Qilu Pharmaceutical Qlaris Bio Qlex QuEEN Qualification QuanBio QuantHealth Quantori Quest Analytics Quest Diagnostics Quotient Therapeutics Qureight Quviviq R&D setbacks R&D shutdown R&D strategy RAS cancer RAS inhibitors RAS-addicted cancers RAS-mutated RAS/RAF inhibitor RBM39 gene RCT RDX-002 RE104 REACH-DMD study REACtiVe-2 REGENERATE-PD RENOIR RESTORE-FA RET protein, human REVEAL-1 REZOLVE-AA REZOLVE-AD RFK Jr. rhetoric RFK Kennedy RGI-C scores RIDDL RIFs RIGL RIPK1 protein, human RIPK2 RIPK2 scaffolding inhibitor RNA Splicing RNA Vaccine RNA delivery RNA drug RNA gene RNA medicine RNA medicines RNA obesity RNA technology RNA test RNA therapies RNA-LNP RNA-targeted medicine RNA-targeting RNAi medicine RNAi medicines ROR1 protein ROR1 protein, human ROS1-positive Lung Cancer ROS1-positive NSCLC ROSA Knee ROSELLA trial RPE cells RPTR-1 RRP RSNA RSV antibodies RSV vaccine RTU cartridges RTW RV-8451 RVO RVU120 RVUs RWE RXRX RZLT Rachael Racism Radar Therapeutics Radiance Biopharma Radicava Radiology Specialty Radiometry Radionuclide therapy Radspherin Rahway Raised Rakuten Medical Rallybio RLYB212 Rancho BioSciences Randomized Controlled Trials as Topic RaniPill Rapid Edge Cloud RapidAI Rating (action) Ratio Therapeutics Ravi Thadhani Readiness Reading (activity) ReadyFlow Autoinjector Rebate Model Rebeca Villarreal-Barragan Receptors, Islet Amyloid Polypeptide Reciprocal Reclassification Recludix Pharma Recognify Life Sciences Recordati Records Recurrence Recurrence Risk Reflex Refractory Plasma Cell Myeloma Regeneron Pharmaceuticals Regulation of biological process Regulatory Authority Regulatory Crackdown Regulatory Expertise Regulatory Framework Regulatory Impact Regulatory Path Regulatory Pathway Regulatory T-Lymphocytes Reindeer Reinvention Relapsed/Refractory Relative (related person) Relay Device Relay Therapeutics Relieving Religious Missions Relmada Relyvrio RemeGen partnership Remote Internship Remote control command - Clear Renal function Renalys Rentosertib Rentschler Rentschler Biopharma Repare Reperio Health Report (document) Research Infrastructure Research Organization Research Projects, R-Series Research Triangle Park Reshma Kewalramani Resistance (Psychotherapeutic) Resistant hypertensive disorder Resolve platform Resources Respiratory Distress Syndrome, Adult Respiratory rate Restricted Resumption Retifanlimab Retinoschisis Retreatments Retro Biosciences Retrotransposons Return on Investment Return to (contextual qualifier) (qualifier value) Reunion Reunion Island Revenue Milestone Reverba Global Reverse Stock Split Revita Reviva Pharmaceuticals Revolution Vibe CT Revuforj Rezatapopt Rezolute Rezon Bio Rezurock Rezzayo Rhode Island Rhythm Ribo Ribupatide Richard Richard Fair Richard Gonzalez Richmond Rick Fair Rick Osterloh Rickets Ridgefield New Jersey Rinvoq growth Risdiplam Rise Up trial Rivus Pharmaceuticals Rob Michael compensation Rob Pinataro Robert Kramer Robert Malone Robert Michael Robert Warner Roche 's Roche Diagnostics North America Roche Tecentriq Rocket Pharma Rocket Pharmaceuticals Roctavian Roger Perlmutter Roivant Sciences Rolvedon Ron Renaud Ronald A. Williams Ronde-cel Roopal Ross Haghighat Rotation Round three Royalty Pharma Royalty-Driven Model Rubella Russia Russian language Ryan Richardson Ryvu Rznomics SABCS25 SAFEbody technology SALT score * * SANDCAT trial SASS SAT-3247 SAVITRI SB-01 SB36 SBA SBX sequencing SC0062 SC451 SCAN disorder SCLC SCN10A gene SCN1A gene SCN2A mutations SCOPE IO SCOPE trial SCOTUS SEC SEED Therapeutics SENS-601 SEP-786 SERENA-6 SERENA-6 trial SERON SGR-2921 SGT-003 SHORE SHP-DB1 SIK2 gene SIM0505 SIM0709 SITC SK Biopharmaceuticals SKB105 SLC17A5 gene SLL SLTE-1009 SLV-154 SLV-324 SMA SOHO SOL-1 SOLAIRIA-1 SOLAIRIA-2 SOLSTICE SPAG8 gene SPG302 SPRB SPaL SRP-1003 SRP-9003 SRSD107 SSGJ-707 ST-01156 STARLYS trial STAT6 STAT6 protein STELLAR-303 trial STI-based STOMP2 STOP-V1 STOP-V2 ) STP-100 STX-001 STXBP1 gene SUCCESSOR-2 SUNY AI Symposium SURMOUNT-5 Trial SURMOUNT-MAINTAIN SURPASS-CVOT SURPASS-PEDS SURVEY.ALSFRSR SW-682 SYD-101 SYNC-T Sabeen Mekan Sackler family SafeBeing platform Safety Data Safety Issues Safety labeling Sagimet Sail Biomedicines Sailaja Battula Sales growth Sam Roosz Samit Samsara Samsung Bio Samsung Bioepis San Rafael Sana Biotechnology Sanacor Sanjay Sanjula Jain-Nagpal Sanofi Blueprint Medicines Sanofi Strategic Sanofi Ventures Sanofi acquisition Santen Santé Ventures Sapablursen Sapio Sapio Sciences Sarah Boyce Sarbani Sarclisa Sarcoidosis, Pulmonary Sarcoma, Epithelioid Sasanlimab Sasineprocel Satellos Scaling Laws Scancell Scheme of Arrangement Schott Schweizerhalle Science of Microbiology Science of genetics Scientific Context Scientific Data Scientific Sessions ScinoPharm Sciwind Sciwind Biosciences Scorpions Scott Howell Screens (device) Scripps Research Seagen acquisition Seattle Office Closure Secondary malignant neoplasm of pancreas Section 232 Sector Security Measures See-Mode Selective Estrogen Receptor Down Regulator Self-Injectable Self-Management Self-injection Self-pay Semerjian Senators Senile cardiac amyloidosis Seno Medical Sensei Biotherapeutics Sensorineural Hearing Loss (disorder) Sensorion Sentynl September 23 Sequestration Seralutinib Serbs Seres Sergio Marullo di Condojanni Series B fundraising Series C financing Series C funding Series D equity Series D1 Series E funding Series F Series F financing Serif Biomedicines Serine/Threonine Kinases Seronegative Sevaro Health Severities ShORe Shandong healthcare Shane Speirs Shankar Ramaswamy Shapes Shareholder Ownership Structure Shareholders Meeting SheMed Sherwin Sattarzadeh Shield Shigella Infections Shigella Vaccines Shin Ashida Shingrix competitor Ships Shock Shooting sensation quality Short Bowel Syndrome Shortened Sialic Acid Binding Immunoglobulin-like Lectins Sibel Health Sickle Cell Siemens Healthineers Signal Signal Transduction Signatera Simplexvirus Simufilam Singapore Single Agent Therapy Single-Domain Antibodies Siran Biotechnology SiranBio Sirexatamab Sirius Sirona Medical Sironax Sitala Site Closure Site of exit Sjögren 's disease SkinJect SkyEngine Slate Medicines Sleep Apnea Syndromes Sleep Apnea, Obstructive Sleep disturbances Sleep medicine specialist Sleeplessness Smart Health Map Smart contact lenses Smoldering myeloma Sobi Social Media Society for Neuro-Oncology Software as a Medical Device Solid Biosciences Solutions Solve Therapeutics Solventum SomaLogic Somatix Sotatercept South Korean biotech Southern Sotho language Spago Nanomedical Spain Sparrow Pharmaceuticals Spatial Mosaic Specialty pharma Specimen Spectral AI Spectrum Profiling Spero Therapeutics Spevigo Spine BioPharma Spinogenix Spiriva Respimat Spondylarthritis Spravato Spring Health Spruce Biosciences SpyGlass Pharma ( SpyLock technology SpyTag/SpyCatcher Squamous cell carcinoma Squamous cell carcinoma of skin Squamous cell carcinoma of the head and neck Squibb Layoffs Squibb partnership Srikanth Pendyala Stabilization Stable angina Standard BioTools Staphylococcus aureus Star Therapeutics StarTrack3 Stargardt's disease State Room Statement Status Quo Steam Stein facility Stelara Decline Stemchymal Step Pharma Stephen Hemsley Stephen P. Dale Steve La Neve Steve St. Onge Steve Tomlin Steve Ubl Stevenage facility closure Stimulation procedure Stipple Bio Stivarga Stock Reaction Stoke Storm Therapeutics' Strategic Deals Strategic Growth Strategy Stratify Dx Strensiq Stress Strive Pharmacy Structure Structure of hippocampal commissure Stryker Stuart Pharmaceuticals Stéphane Bancel Subacute Care Subcutaneous Cancer Sublocade Subsidies Substance Abuse Detection Substance with human epidermal growth factor receptor 2 inhibitor mechanism of action (substance) Substance with programmed cell death protein 1 inhibitor mechanism of action (substance) Summer SunRISe-1 trial Suneet Varma Sunita Mishra Super Bowl 2025 Super Bowl ads Superficial ulcer Superluminal Medicines Supernus Supervisory Board Supply chain disruption Support Services Program Supportive care Supranuclear paralysis Supreme Court stay Surgeon Surgical Replantation Surgical Robot Surrogate Surveillance: safety Susan Susvimo Sutro Suvretta Capital Management Suzanne Winter Swift Medical Swift Ray SwiftFluo Swissmedic Swixx Group Sydnexis Sylvia Isler Symptomatic SynAIRgy SynKIR-110 SynKIR-310 Synapse AI Synbio International Inc. Syncromune Syndax Syndeio Syngene Synnovation Syphilis, Congenital SystImmune T business T cell therapy T cell-targeted T-Bolt T-Charge T-DXd T-cell malignancies T-cell therapy TA-ERT TACTI-004 TAF8 wt Allele TAILORED-AF TAK-861 TAS-205 TB Alliance TB-500 TCEs TCR TCR-NK cell therapy TECVAYLI TECregen TESARO TETON-2 THB335 THETA platform TIDAL-01 TIGIT antibody TIL cell therapy TJ Biopharma TLN-121 TLN-254 TLN-372 TLX2 gene TMP-301 TOGETHER-PsO TPRG1L gene TR-FRET TRANSCEND TRANSCRIPTION FACTOR TRBV9 gene TREX1 gene TRICORDER TRIM21 TRIMTAC TRONTIER TRPC6 inhibitor TRPV4 protein, human TRVI TRiM platform TSHA-102 TScan Therapeutics TTAM TTR wt Allele TULIP-SC trial TV ad TYK2 Inhibitor TYK2 inhibitor TaiGen Biotechnology Takeo Takhzyro Taltz Tampa Florida Tanabe Pharma Tang Tanruprubart Taxes Taysha Gene Therapies Tecan Tech Rivalry TechLive Ted Love Tedopi Teijin Teladoc Television Tempero Bio Tempus Tender Tenvie Tepkinly Termination - Inactive Reason Code TerraBind Terremoto Terry Fox Research Institute Testiculo- Testing Texas Facility Texas Tech Thad Huston Thakkar Therapeutic Antibody Therapeutic radiology procedure Theravance Biopharma Thetis Study Thick Third Circuit Court Third Harmonic Bio liquidation Third line treatment Thomas Hartung Thomson Reuters Thousand Oaks Thrombotic Stroke Thyme Care Thyroid Diseases Tidmarsh Tim Van Hauwermeiren Timothy Wentworth Tinnitus Tiragolumab Tissue damage Titania Titles Tiziana Life Sciences Tokyo Stock Exchange Tomi Sawyer Tonix Tonmya Topco Tortugas Toru Ashida Total Improvement Score Tourette 's syndrome Tourmaline Bio Toxic Epidermal Necrolysis Toxic Oligomers Toxicology Tozorakimab TraceNET Tracer Tracy Beth Heg Traditional Medicine Trail Making Test Transcarent Transcranial magnetic stimulation Transdermal Route of Drug Administration Transfection Transfer RNA Transformation Officer Transformational Data Transforming RNA Medicine Development Translational Oncology Transplantation Transposition of Great Vessels Trastuzumab Rezetecan Travel Health Treating Treatment Adherence Treatment Effectiveness Tregs Trevi Therapeutics TriNetX Trial Phase Trial Termination Trinity (ethnic group) TruTCR Trump 's Trump administration reforms Trump administration tariffs Trump budget Trump executive order Trump import tariffs Trump policies Trump tariff Trust (Social Behavior) Truvada Truveta report Tukysa Tumor Microenvironment Tumor Suppression Tumor board Tumor stage Tis Tumor-Infiltrating Tumorad-01 Tumorigenicity Turbine Turitz Tyler Sloat Type A meeting Type II JAK inhibitor Tyruko Tysabri Tyvaso Tzield U.S. Food and Drug Administration UCCD UK 's UK-US UNLOXCYT UPB UPCR US-China competition US-EU UTP-monosaccharide-1-phosphate uridylyltransferase activity UgeneX Ugur Sahin Ultomiris Ultreon 3.0 Undetectable Unicorn births Uninsured United Imaging Healthcare United Laboratories International Holdings Limited United States Agency for International Development Universal Universal Cells University of California Unixell Biotech Unravel Unspecified Abortion Updates Upstream Bio Uptake Urcosimod Urinary Bladder Urinary hesitation Urine culture Urology Urticaria Urticaria due to cold Usher Syndrome Type 1B Usona Institute Uwe Buecheler VAL-413 VALOR VALOR study VAV1 protein VAX-24 VAX-31 VAY736 VAYHIT2 trial VCT220 VDPHL-01 VENT-02 VENT-03 VESALIUS-CV trial VESPER-3 VGA039 VHH VHH Immunoglobulin Fragments VISTAS study VIZZ VLA15 VMAT2 Inhibitor VMX-C001 VRDN-003 VX-993 VY1706 VY7523 VY9323 VYJUVEK Vaccination Hesitancy Vaccine Efficacy Vaccine Reform Vaccine Testing Vaginal Microbiome Valar Labs Valiltramiprosate Valinor Vamikibart Vanda Vanderbilt University Medical Center Vanrafia VantAI Variant Variant Bio Variation (Genetics) VarmX Vascular anomaly Vaseline Vasudev Bailey Vaxcyte VectorY Veeva Systems Veklury VelaVigo Vemircopan Ventana Medical Systems * * Veraxa Verification Verily Verily Me Verismo Therapeutics Versant Vertex Veru Verzenio Vesta <beetles> Vestibulo-Ocular Vevzuo ViVac Pharma Viable Viatris Vibrance-1 study Vicebio Vidofludimus Calcium View Bora ViewPoint EchoPilot Viewer Device Vigil Neuroscience Vimseltinib Vinay Prasad FDA memo Vincentage Vincentage Pharma Vineet Agrawal Violence Violet AI Viome Viralgen Virginia Virginia facility Virginia plant Viridian Virtual Cell Model Virtual Geneticist Virus-Like Particle Visible Vision Restoration Vistagen Visual Suppression Visugromab Vital capacity test Vitiligo Vitor Roque Vivtex Voluntary Scheme Vomiting Vor Bio Voucher Voxzogo Voyager Therapeutics Voyxact Vunakizumab Vyglxia Vyondys 53 Vyvanse Vyvgart Hytrulo WARN WARN filing WARN notice WEE1 WEE1 inhibitor WHIM syndrome WP1066 WVE-N531 Wakefulness Test Walgreens Boots Alliance Walmart partnership War-Lock platform Warning Letter Warsaw-Duchnice Washington state WeDosify Wearable Behavior Model Wearable Electronic Devices Wearable biosensors Web Site Wehr Weight Watchers Weldon Weldon 's Welfare Werner Syndrome Werner helicase Westborough Massachusetts Western biotech Western patients Wet AMD Wet Age-Related Macular Degeneration White House liaison William Blair Wilmington Windward Bio Withdrawal Symptoms Wolfgang Wienand Women Workforce Working Group World WorldMeds Wounds - qualifier Written - Consent Mode Wuhu X-Cell X-Linked X-linked retinitis pigmentosa XHANCE XOMA XOMA Royalty XPro XR Xaira Therapeutics Xanthomatosis Xarelto Xarelto patent Xenograft procedure Xenon Pharmaceuticals ' Xevinapant Xianweiying Xilio Xolair Xolremdi Xpovio Xpress Wellness Xspray Pharma XtalPi Y-mAbs Y220C mutation YB-101 Yarrow Bioscience Yervoy Yidafan Yosemite Young Adult Young Talent Yupelri Yvonne Greenstreet Z-1018 ZENEO® ZENITH trial ZEPIZURE ZG006 ZI-MA4 ZIMA-101 ZM-02 ZUSDURI ZW171 Zaka Zami Aberman Zanidatamab Zegfrovy Zelgen Zelis Zelluna Zemaira ZenGUARD Zenkuda Zentalis Zentek Zepbound KwikPen Zephyr AI Zepzelca Zervimesine Zhongmou Zifo Zilebesiran Zilganersen Zilovertamab Zokinvy Zongertinib Zonsen PepLib Zoë Zuellig Pharma ZyDoc aDBS aGvHD aTyr abdakibart abelacimab acasunlimab acceptance access strategy accessible aceclidine acquisition talks acquisition termination active pharmaceutical ingredients activin signaling acute graft acute systemic infection adaptive deep brain stimulation adaptive dosing adeczibart adjunctive treatment adjuvant Tecentriq adjuvant setting adjuvant treatment admilparant administrative law administrative proceedings adulteration advanced breast cancer advanced manufacturing advanced solid malignancies advanced solid tumors advisory advisory appointments aesthetic treatments affairs aflibercept age restriction age-related diseases agency departures agency instability agency staffing shortages aggregator agile agilon aging-related diseases aglatimagene aleniglipron all-cash tender alliance allogeneic cell therapy allogeneic hematopoietic stem cell transplant with purging alpha opportunities alpha radioligand therapies alpha radiopharmaceutical alpha-synuclein antibody alternative testing alternatives ambulatory care services ametefgene parvec amezalpat amivantamab ampreloxetine amsacrine/azacitidine/etoposide amycretin amyloid beta antibody amyloid-beta amyloid-lowering drug anaphylaxis anifrolumab anitocabtagene autoleucel annamycin anti-APRIL antibody anti-CD47 monoclonal antibody anti-TL1A anti-TSHR antibody anti-VEGF therapy anti-amyloid antibody anti-amyloid drugs anti-fibrotic anti-vaccine movement antibody candidates antibody collaboration antibody design antibody engineering antibody humanization antibody reactome antibody therapeutics antibody-chopping drug antibody-targeted antisemitism antisense antithrombin III antitrust litigation anvumetostat apatinib apecotrep apomorphine hydrochloride applicability application assessment appropriations approval status approval sweetener argenx Vyvgart aroxybutynin artemether-lumefantrine artificial luciferases aseptic manufacturing asset acquisition asset termination assumes assurance at-home at-home colon cancer at-home screening at-home treatment ataluren atlases atomoxetine attraction attractiveness auction autoimmune drugs autoinjectors autologous cell therapy autologous neurons autonomous avibactam azetukalner aztreonam b.well partnership backer bacterial detection baldness cure bankruptcy filing becton dickinson belumosudil bemarituzumab benefit-risk profile benralizumab bespoke bevacizumab bexmarilimab bile acid therapy bile duct syndrome biliary cholangitis bimagrumab bimatoprost IOL biochemical recurrence bioequivalence bioequivalence testing biofilm-driven chronic respiratory disease biologic blockbusters biomanufacturing jobs biomarker qualification biomarker test biomarker testing biomedical foundation models biomedical innovation biomolecular structure prediction biopharma agents biopharma exit strategy biopharma financing biopharma fund biopharma industry biopharma job biopharma regulation biopharma startups biopharma survey biopharmaceutical company biopharmaceutical innovation biopharmaceutical partnership biopharmaceutical sector biopharmaceutical startups bioprocess bioprocessing biosimilar competition biosimilar guidance biosimilarity biosimilars approval biotech careers biotech closure biotech collaborations biotech dealmaking biotech employment biotech executive biotech finance biotech financing biotech incubator biotech leadership biotech licensing biotech pivot biotech spinoff biotech strategy biotech workforce biotechnology innovation biotechnology layoffs biotechnology partnerships bipartisan criticism bird flu vaccine birtamimab birth dose bispecific bispecific antibody screening bispecific antibody technology bispecific competition black-box warning blockbuster drug blockbuster sales blocker blood clotting drug blood pressure ambulatory blood pressure pill blood sugar control blood vessel disorders blood-based cancer board members board restructuring board shake-up bone lesion prevention bonus boost booth bortezomib brain fluid brain organoids brain shuttles brain volume brain-penetrant brain-penetrant delivery brand-name drugs brand-name prescriptions branded medicines briquilimab broaden business options business plan business practices business split business strategy business unit butyrophilin superfamily cGAS inhibitor cGVHD cUTIs cabotegravir calcium campaign campaigns canakinumab cancellations cancer antigen therapy cancer diagnostics cancer drug sales cancer funding cancer intelligence cancer prediction cancer proteins cancer research trends cancer testing cancer therapeutics cancer treatments cancer trials capacity quadruple capital constraints capital investment capivasertib cardiac research cardiac safety cardiac safety signal cardiometabolic care cardiorenal medicine cardiotoxicity screening cardiovascular asset cardiovascular benefits cardiovascular gene therapy cardiovascular safety cardiovascular screening cardiovascular trial career cargo receptor ligand activity cartilage degradation carve-out casdatifan cash balance cash-paying cell analysis cell classification cell therapy manufacturing cell therapy sale cell therapy sales cell transfer cell transformation cell-associated neurotoxicity cell-device combo cell/gene therapy cellular rejuvenation cema-cel cemdisiran central reads central subfield central venous catheter (CVC) sets cerebrotendinous xanthomatosis cetuximab chairman resignation charmed checkpoint inhibitor-resistant chemical alternatives chemical space chemo-displacement chemo-turned-gel drug chemotherapy-free regimen chenodeoxycholic acid childhood health chinese medicine cholesterol ester transfer protein inhibitor cholesterol-lowering choline chronic disease epidemic chronic disease management chronic graft-versus-host disease chronic health conditions chronic hives cisplatin-eligible cisplatin-ineligible citizen petition civil class action clawback rate clazakizumab clean sweep clemidsogene lanparvovec cleminorexton click clinic entry clinical AI clinical diagnostics clinical holds clinical improvement clinical operations clinical outcomes clinical remission clinical reproducibility clinical research services clinical results clinical seizure clinical terminology clinical trial conduct clinical trial halt clinical trial pathway clinical trial results clinical trial review clinical trial update clinical update clinical visualization clinical worsening clinical-stage clinical-stage AI startups clinical-stage biopharma clinical-stage biopharmaceutical clinical-stage biotech clinical-stage companies clinical-stage company clinical-stage immunotherapy clinical-stage pharmaceutical clinicogenomics clofutriben clone stability closed-loop interventions closed-loop systems co-development co-exclusive license co-location coalition cognition cognitive improvement cognitive side effects collaborative framework collaborative healthcare coloplast commercial supply chain commitment community grants community-oriented clinical trials companion diagnostics company closure company transformation competitive weight loss medication complement system complete responses compounding pharmacy computational drug discovery computational pathology computational protein design computational protocol concept concessions conditional approval pathway conditioning regimens confidentiality confirmatory study conservative criticism conspiracy constitutional challenge constitutionality content intelligence contextual errors contingent value contingent value rights continuous contract cancellation contract extension contract manufacturer controllable controversy conversation conversion factor convertible cooperation copper histidinate copper isotopes cornea surgeon corneal endothelial disease coronary imaging coronary trial corporate development corporate governance cortisol modulator cost reduction cost-cutting initiatives cost-effectiveness cost-reduction cost-saving country-of-origin labeling covalent binding drugs covalent biologics covalent chemistry cranial neurosurgery crash craving control credit card fees critical bleeding crizanlizumab crofelemer cross-border cross-border pharma ctDNA-guided therapy customer-facing organization customs loophole cutaneous remission cyclic adenosine-5'-trimetaphosphate cyclobenzaprine cynicism cytisine cytotoxic T-lymphocyte antigen 4 daily pills daisy danegaptide daratumumab daridorexant data bottlenecks data gaps data harmonization data misinterpretation data modernization data secrecy data solutions data stewardship data-driven decisions data-driven innovation de novo design de novo miniproteins deal activity deal termination death risk reduction debt maturity extension debt obligations debut deceptive marketing decision day decision delay decision science decitabine deficiencies delgocitinib demerger demyelination dencatistat depression drug deprioritization deruxtecan-nxki developmental restoration device regulation diagnostics industry digital coaching digital enablement digital endpoints digital health records digital health regulation digital health screener digital infrastructure digital medicine digital microfluidics digital pathology prognostic test digital quality systems digital solutions digital tools digital twin dimethylethylsilylimidazole direct-to-consumer ( DTC ) direct-to-employer direct-to-patient model director firing directors disability services disease activity disease awareness disease clinical trials disease control rate disease drug disease program disease research disease therapies disease treatment disease vouchers disease-modifying treatment disorder control (procedure) dissolvable distributor network divestiture docetaxel domestic pharmaceutical industry domestic production domestic supply chain doravirine doravirine/islatravir dotinurad doubt downsizing downturn draft report drug activity drug ads drug affordability drug application drug approval outlook drug candidates drug combo drug competition drug conjugates drug delivery innovation drug delivery platform drug development pipeline drug development sentiment drug discontinuation drug discount program drug failure drug import duties drug importation drug imports drug ingredients drug lag drug licensing drug manufacturers drug optimization drug pipeline drug price negotiation drug pricing plan drug production drug quality drug rebates drug rejections drug relabeling drug reviews drug sales drug-resistant drug-resistant TB drug-resistant focal seizures dual pathway inhibition dual-payload ADC dual-payload technology dual-targeting dual-targeting CAR-T dulaglutide dwarfism trial e-posters eGenesis eRNA earlier-line treatment early disease early-phase trials early-stage trial earnings beat ecnoglutide efdoralprin alfa efimosfermin alfa efzofitimod elebsiran elecoglipron electronic health record - ActClassContainer elenestinib elinzanetant eloralintide elranatamab emergency medicine (field) emiltatug ledadotin employee layoffs employment employment reduction emugrobart enLIGHTEN Discovery Platform enforcement letters enfortumab enfortumab vedotin engine engineered peptides enlicitide decanoate enobosarm enrollment forms enrolment entera enterprise reorganization entry - ActRelationshipCheckpoint environmental enzyme engineering enzyme restoration enzyme technology eosinophil epigenetic modulator epigenetic therapy epinephrine equity buyback equity financing equity upside ersodetug esreboxetine estate estrogens etanercept evaluation event cycle evidence-based evolocumab exagamglogene autotemcel exclusivity extension executive actions executive changes executive exits executive survey executive team executive vice president existential threats expanded label expansions expedited pathway expertise experts expirations exploitation external control group external controls external partnerships extrahepatic RNAi eye treatment eyonis facilities facility closure facility consolidation factor XIIa factory closure fam-trastuzumab fantasy-romance farabursen farm-to-hospital faster fat loss fat reduction federal agencies federal courts federal directives federal workers fee structure fenebrutinib fentanyl fibroblast immunology fibrodysplasia fibrosing fidrisertib field ablation figures filing checklist final analysis financial guidance suspension financial outlook financial recovery financial strategy financial struggles financial troubles financing strategy finerenone firi-cel firing first-in-class antibiotic first-line maintenance fiscal flagship office flaws flu/COVID-19 foreclosure proceedings foreign direct investment foreign factories formula update formulary exclusion formulations four-letter suffix franchise frataxin frataxin protein fratricide-resistant full-year guidance function functional cure funding agreement funding bill funding environment funding lapse funding rounds fungal prophylaxis gains gamgertamig gamma secretase inhibitor gamma-linolenic acid garadacimab-gxii gastric inhibitory polypeptide receptor gastroenteropancreatic neuroendocrine tumors gastrointestinal gemcitabine gemcitabine intravesical system gemcitabine releasing system gene delivery process gene modulation gene variants gene writing gene-editing therapy generative design generative models generic competition generic manufacturing generic medications genetic cell genetic diagnosis genital lesion reduction genome engineering genome screening genomic analysis genomic drug discovery genomic medicines genomics AI genotoxicity geopolitical factors geopolitical risk gildeuretinol glatiramer acetate global commercialization global competitiveness global drug development global drug pipeline global growth strategy global headquarters global health programs global health security global license agreement global network global price global sales global strategic R&D center global strategic collaboration global strategic partnership global strategy global trade tensions global trial global workforce reduction glycoengineering glycosylation go-to-market models golden decade golimumab government events government programs government review governmental engagement grace granite grant cancellation green energy green list green manufacturing gross profit growth Z-score growth drivers growth opportunities guidance raise guidance upgrade guidances gusacitinib hair loss treatment halt hand sensation harassment head-to-head trial headcount health coverage health data privacy health industry health prediction health system partnerships health systems health tracking health workers healthcare AI healthcare IT healthcare agencies healthcare analytics healthcare appointments healthcare benchmark healthcare budget healthcare changes healthcare executive healthcare finance healthcare financial performance healthcare funding healthcare infrastructure healthcare investment healthcare legislation healthcare marketing trends healthcare operational healthcare operations healthcare payments healthcare trends healthcare workflow healthy lifespan healthy longevity heart drug height velocity hematologic cancers hematologic care hematoxylin and eosin ( H&E ) stained hemoglobin response hemophilia A program hepatitis B policy change heroin herpesvirus 2, human heterozygous high-dose high-dose regimen high-performance computing high-throughput higher risk hiring challenges hold-and-kill homegrown hormone receptor-positive hospital apps hospital intervention hospital nutrition host disease human-relevant models huntingtin-lowering hyaluronidase hydroxyurea hyper-personalized engagement hyperscaled data iMTP iPSC-derived iPSCs iSCIB1 + illegal immigration iloperidone iluzanebart image management imaging AI immune compromise immune disorder therapy immune profiling immune protection immune signaling pathways immune system reprogramming immune-mediated diseases immuno-dermatology immunoglobulin G immunotherapy drugs implantable device implementing import rules import taxes impurity in situ in vivo studies inclacumab incretin secretagogue incretin therapy indictment individual choice individual-based decision-making induction trials infant infestation infigratinib influenza prevention infringement inhaled drugs inhaled lung disease inhaled therapies inidascamine initiation protocol innovate innovation centre innovative drugs innovative medicines innovative trial inorganic pyrophosphate insider insider trading insolvency insulin delivery insulin icodec-abae insulin production integrated decision-making integrated solutions interferon pathway interim interleukin-11 interleukin-12 interleukin-23 receptor activity interleukin-3 interleukin-4 intermediate-risk internal disagreement internal rate internal tensions international operations international pricing international trade internet phrase internship intisemeran intra-abdominal infections intraoperative guidance intrathecal delivery intrathecal formulation intravenous formula investing investment grants investor rescue investor sentiment islatravir isolator technology itolizumab ixekizumab ixovec iza-bren judgment jumping gene jumping genes jurisdiction kickback scheme kidney drug kidney therapeutics kilobase pairs kinase inhibitor [EPC] kyron.bio lab space label extension label update labeling change labeling changes laboratory modernization laboratory reform programme lack of lack of transparency lanifibranor large-scale manufacture laru-zova late recurrence risk late-stage assets late-stage clinical development late-stage testing layoff leaders lecanemab-irmb legal victory legality lender takeover lentiviral vector lentiviral vectors letrozole leuprolide levacetylleucine license suspension licensing restrictions lidERA life science incubator life sciences fund life-extension life-saving medicine likeability lincomycin linezolid liquidation listings live event liver enzyme elevation liver-targeted RNAi loan financing localization locally advanced head loncastuximab tesirine long-acting long-acting injectable long-acting injectables long-acting protection long-acting therapies long-acting therapy lonvo-z lorlatinib loss of function loss treatment lotiglipron low low-cost lower dose lung scarring lunsekimig lupus skin drug lurbinectedin lymph nodes lymphocyte immune globulin, anti-thymocyte globulin lymphocyte-activation gene 3 protein lymphocyte-activation gene 3 protein, human mAbxience mCRC mCombriax mFARS mNEXSPIKE mRESVIA mRNA contracts mRNA misinformation mRNA production mRNA therapy mRNA-1083 mRNA-1283 mRNA-1647 cytomegalovirus vaccine mRNA-4359 mRNA-based mRNA-based Personalized Cancer Vaccine mRNA-4157 macroeconomic macular maintenance trial management layers management technique mandates manufacturing campus manufacturing challenges manufacturing closure manufacturing consolidation manufacturing deficiencies manufacturing license manufacturing practice manufacturing shutdown manufacturing uncertainty marketing authorisation marketing officer marketplace marstacimab mast cell therapy match Eylea maternal-fetal monitoring mazdutide measles, mumps, rubella, varicella vaccine measurable outcomes med-tech medical advancements medical breakthroughs medical data medical device company medical documentation AI medical freedom medical groups medical jargon medical leadership medical review medical supplies medical supply chain medical technology exemptions medical wearables medtech industry meeting cancellation mega depots melanin-concentrating hormone membranoproliferative glomerulonephritis men 's health menen inhibitor mental health innovation merger cancellation mesothelin metabolic dysfunction-associated steatohepatitis metabolic health metabolic medicines metagenomic sequencing methylone mezigdomide mezigitamab mice studies microdosing microenvironment microneedle patches microneedles microparticle technology microservices mid-2030s mid-stage middle dose middle-income countries middlemen midline glioma midterm milestone payment milsaperidone mini-proteins minimis exemption minimization missed milestone mitazalimab mivelsiran molecular entities molecular glue degrader molecular modalities molecular point-of-care molecular residual disease month most-favored most-favored-nation pricing motor fluctuations motor milestones mouse models movers mucosal healing multi-agent system multi-agent systems multi-cancer early detection multi-cancer screening multi-cancer tests multi-institutional research multi-medicine platforms multi-omic strategies multi-payload multi-program collaboration multi-sensor multi-specific antibodies multi-year collaboration multibillion-dollar market multiforme multimodal approach multimodal data multiplex test muscle health muscle loss muscle strength endpoint muscle-invasive musculoskeletal conditions myQA StarTrack myelin repair myosin inhibitor myostatin antibody nHCM naloxegol naltrexone-bupropion naming convention nano-in-micro delivery nanobody nanodelivery nanoparticle delivery nanosecond naproxen-n-butyl nitrate narsoplimab nation policy national priorities national priority review voucher national priority review vouchers national sector growth nations nature-inspired drug discovery navenibart needle-free vaccines negative opinion negotiators neladalkib nemolizumab neo-epitope cancer vaccine neosubstrate neuro injury neuro pipeline neuro-metabolic diseases neuro-rare diseases neuro-specialty diseases neurofibroma neuropathic corneal pain neuroprotective neuropsychiatric disorders neuropsychiatric drugs neuroreparative therapeutics neuroscience division neurotechnology neurovascular AI neutrophil-mediated disease new product newco nexiguran nexiguran ziclumeran next-gen brain therapies next-generation Covid vaccine next-generation drugs next-generation sequencing next-generation vaccine nintedanib nipocalimab-aahu nirsevimab nizubaglustat nmHSPC nodularis nomination committee non-European ancestry non-FDA non-antipsychotic non-competitive profile non-cystic fibrosis bronchiectasis non-dilutive non-dilutive financing non-generic specialty non-hormonal therapy non-incretin therapies non-inferiority non-mRNA vaccine non-metastatic non-opioid non-opioid pain medication non-opioid pain relief non-opioid pain therapies non-relapsing secondary progressive non-surgical back pain noncirrhotic nonprofit webinars nonrelapsing nonsurgical treatment options normative wakefulness nucleic acid delivery nusinersen obesity therapy obesity-related cancers obsidian ocadusertib ocular adverse events ocular immunology off-target offerings office closure offloading offshore older children oligomer selectivity olverembatinib omnichannel on-demand once-daily pill once-yearly oncology advancements oncology company oncology decisions oncology diagnostics oncology ecosystem oncology expert oncology licensing deal oncology market oncology pivot oncology portfolio oncology supply oncology therapeutics oncology trials oncolytic immunotherapy online program ontunisertib open innovation open science open-label extension open-source AI open-source dataset openFDA operating costs operating expenses operating profit margin operational efficiency operational transformation ophthalmic preparation optimisation programme opto-acoustic imaging oral FASN oral PCSK9 oral asthma therapy oral carbapenem oral cholesterol pill oral drugs oral formulations oral inhibitors oral minoxidil oral obesity drug oral peptide oral pill vaccine oral regimen oral small-molecule therapeutics oral small-molecule therapy oral weight loss drug orchestration orelabrtuinib orexin agonist orexin receptor type 2 organ donor organic growth orglipron orphan drug exclusion orthopedic innovation osavampator ossificans otoferlin out-licensing overall response rate overcapacity overhaul overhype overmedicalization overseas oversubscribed fund ownership increase ozekibart ozureprubart p-tau217 p53 reactivator pTau217 packaging issues pain assets pain crises palivizumab pamirtecan pan-JAK inhibitor pan-KRAS pandemic influenza partial response partnering with pasritamig patent expiration patent license pathology AI patient definition patient management patient meals patient navigation patient populations patient recruitment patient-provider interaction patient-specific therapies patient-specific therapy patritumab pattern hair loss pause recommendation payer paying payload peak sales pediatric brain cancer pediatric diseases pediatric drug designation peer pelareorep penicillin recall peptide therapeutics personal data personal genome service personalized cancer therapy personalized care personalized health services personalized healthcare personalized neuromodulation personalized treatment personnel change perspectives pertuzumab petition pharma TV ads pharma brand engagement pharma companies pharma consolidation pharma division pharma industry pharma investments pharma packaging pharma patent expirations pharma policy pharma reforms pharma reshoring pharma response pharma skills shortage pharma tech pharma trade group pharmaceutical AI pharmaceutical advertising crackdown pharmaceutical backing pharmaceutical collaboration pharmaceutical commercialization pharmaceutical communications pharmaceutical delays pharmaceutical delivery pharmaceutical divestment pharmaceutical earnings pharmaceutical employment pharmaceutical imports pharmaceutical investment pharmaceutical lawsuits pharmaceutical leadership pharmaceutical licensing pharmaceutical lobby pharmaceutical market pharmaceutical mergers pharmaceutical milestones pharmaceutical rebates pharmaceutical revenue pharmaceutical setback pharmaceutical setbacks pharmaceutical trade pharmaceutical trade war pharmacy platform pharmacy reimbursement phase 2/3 trial phase 3 failure philanthropy phosphodiesterase 4B pimecrolimus pipeline blips pipeline cull pipeline gaps pipeline management pipeline restructuring pipeline setbacks pipeline shake-up pipeline shift pipeline update pituitary adenylate cyclase activating polypeptide pivot resources pizuglanstat plant construction plasma-derived therapies plasma-derived therapy platelet levels platform immunotherapy * * pledge pneumococcal conjugate vaccines podcast political poly-N-4-vinylbenzyllactonamide portfolio companies portfolio prioritization portfolio reprioritization portfolio support posdinemab post-COVID post-marketing requirement post-marketing studies postprandial povetacicept pozdeutinurad practice expense practice-changing pre-IPO pre-IPO ' precision cancer precision neurology preclinical CRO preclinical drug preclinical pipeline preclinical program preclinical research preclinical studies predictive pregnancy detection pregnancy screening preliminary injunction premium presbyopia prescribers prescribing habits prescription drug ads prespecified pretomanid preventive services panel price controls price decline price hike price transparency pricing flaw pricing policies pricing pressures pricing reform prioritization priority brands priority vouchers private block trade proactive care product hopping product strategy profit margin profitability programmable RNA medicines programmable biology progressiva project cancellation propane propiolactone protections protein compounds protein drug discovery protein elimination therapeutics protein folding protein levels protein science protein structures protein-based vaccine protein-ligand datasets protein-ligand prediction provider operations pseudobulbar psychedelic medicine psychedelic supply psychiatric trials psychiatry pipeline public biotech public companies public company public health agencies public health crisis public health debate public health guidance public health leaders public servants pulsed field ablation pure-play strategy quality assurance quality control violations quantum phenomena questions radiation-free imaging radical transparency radiographic remission radioisotope supply chain radiological imaging radiotheranostics radiotherapeutic radiprodil ranibizumab rare blood disorder rare disease reSET (device) real-estate real-time real-time clinical trials real-time disclosure real-time publishing realistic medical scenarios rebate rate rebate schemes rebranding reciprocal tariffs recognition recombinational repair recurrence-free survival recurrent astrocytoma redesable eye drop reduction in force reform reforms refractory myeloma refusal-to-file regenerative cell therapy regulatory AI frameworks regulatory RNA regulatory advocacy regulatory alignment regulatory barriers regulatory certainty regulatory change regulatory changes regulatory complexity regulatory consulting regulatory decision regulatory disclosure regulatory dynamics regulatory governance regulatory harmonization regulatory hurdle regulatory hurdles regulatory innovation regulatory law regulatory meetings regulatory reform regulatory reforms regulatory standards regulatory streamlining regulatory transparency reinstatement relapsed/refractory large-B-cell lymphoma relapsed/refractory multiple myeloma relatlimab remote scanning remternetug remyelination renal response renewal representatives reproductive health biotech repurchase reputation rescheduling rese-cel research discontinuation research instrument development research partnerships research retraction research study research universities resignations resource shortage respiratory vaccines respiratory virus season restraining order restricted population restructuring charges resume analysis revakinagene taroretcel-lwey revamp revenue dip revenue guidance cut revenue target revumenib revyve rezafungin ribonucleoside-diphosphate reductase activity rilvegostomig risk-based risk-based oversight risperidone risvodetinib rivalry robotic HIFU robotic automation robotic knee replacement roll-ups romantasy ' rondecabtagene autoleucel roundtable royalty acquisition royalty management royalty monetization rubrics rural healthcare ruxolitinib safety signal salanersen sale rule sales guidance salicylhydroxamic acid sample stabilization satralizumab scFv scPharmaceuticals scSurvival scale-up scaling not solving scandal scenario school meals science-led storytelling scientific advisors scientific discovery scientist protest scrutiny search - EntityNameUse seasonal flu secondary blood cancers secondary markets sector rotation secured secured debt securities fraud seed financing seed investments seizure drug seladelpar self-administered drug self-administration self-collection devices self-injectable self-injection business self-injection systems self-paying self-serve self-service semiconductor supply chains semiconductor tariffs sensor (device) sequence-based AI serono setback setrusumab seventh shadow AI shakeup sham surgery sham-controlled trial shareholder value shortage shrinking shrinking budgets shutdowns shuttles sigma-2 receptor single-cell RNA sequencing single-dose vials sirolimus site closure site transfer skin clearance skinny label sleep biotech small molecule agonists small molecule candidates small molecule design small molecule drug discovery small molecule drugs small molecule inhibitors small molecule medicines small molecule therapies social disadvantage software-as-a-medical-device solid cancers solid tumor cancer solid-state batteries somatic genomics somato-cognitive action network somatropin sonrotoclax soquelitinib sorfequiline sortilin sotatercept-csrk sotorasib spatial profiling spatial proteomics specialty diseases specialty drugs spectral imaging spesolimab spin-out spinoff spleen exam splicing correction spotty complaint reporting staff exclusion staff reduction staff reorganization stage IV reduction stake stake sale stance standards characteristics statistical methods stealth stem cell-derived islet cells stem cell-secreted proteins sterile cartridge facility sterile manufacturing steroid-sparing stock plunge stock price stock purchase stock repurchase programs stock sale stock sales stock slide stock slip stockholder stockpile stockpiling strain Big Pharma market pressures strain selection strategic advisory strategic alignment strategic collaborations strategic decision-making strategic investors strategic options strategic overhaul strategic pivot strategic plan strategic reserves strategic transformation strategy streamlined process streamlined review streamlined system stroke trial structural changes subcutaneous administration sublingual tablets submission delays submission program succession planning suicide suicide warnings sunitinib sunvozertinib superbugs supercomputer superiority trials supply chain exposure supply chain management supply chain resilience supply chains supply shortages supply suspension suppurativa surgical planning surrogacy surrogate endpoint surveillance aspects survival data survival rate survodutide sutacimig suvorexant sweat sensors synovial fibroblasts synthetic construct synthetic royalty syphilis treatment takeover tarcocimab tedromer target-effector pairs targeted alpha therapy tariff avoidance tariff exemptions tariff increase tariff pause tariff threat tarlatamab-dlle tau therapy tau-targeting tau-targeting antibody team transformation tech partnerships technology innovation technology summits teen suicide tenofovir tenofovir disoproxil fumarate tenure terminated - RoleStatus therapeutic antibodies therapeutic development therapeutic diversification therapeutic payloads therapist thermal imaging theta/beta ratio three-year thrombotic disease thymic stromal lymphopoietin thymus regeneration thymus-targeted thymus-targeted therapy ties time acceleration tissue models tobevibart tonlamarsen top-selling drugs topical amitriptyline topical treatment total health toxicity profile trade agreement trade compliance trade deficit trade deficits trade policy trade secrets trading training data trans-splicing ribozyme transatlantic trade transdermal cannabidiol gel translational translational biology transposons trauma qualifier traveler treatment approval treatment discontinuations treatment prediction treatment resistance treatment scaling treatment-resistant hypertension trial failure trial results trial site irregularities triple hormone receptor agonist triple seronegative triple therapy triplet therapy tumor control tumor response tumor shrinkage tumor-specific antigens turbulence turnaround strategy twice-yearly type I uACR uUTIs ultra-long acting ultra-rare disease ultra-rare diseases ultra-short regimen unanimous vote underregulated underwritten unicorn startup union strike universal recommendation university lawsuit unmet unreliable unreported deaths upfront cash upfront discounts upgrade upheaval upsized urgent care visits urothelial cancer ursodiol utilization qualifier uveitic macular edema vIGA-AD vaccine advisors vaccine advisory panel vaccine agenda vaccine alternatives vaccine approval vaccine delivery vaccine framework vaccine guidelines vaccine industry vaccine injuries vaccine licensing vaccine misinformation vaccine oversight vaccine pipeline vaccine policy vaccine programs vaccine regulation vaccine skepticism vaccine standards vaccine trial valbenazine valley of death value maximization value-based contracts value-based pricing valve disease varegacestat vascular deposit binding vascular intelligence vascular intervention vascular leakage vaso-occlusive crises vector vectorized veligrotug vendor-agnostic verekitug vial stopper defects vidofludimus vilobelimab violation viral shedding viral suppression virtual diagnosis vision improvement visual computing vitamin B12 vobra volixibat vorolanib vosoritide vote voting voxelotor wage waveLINE-003 wear time wearable biosensor wearable regulations wearable sensors wearable technology healthcare wearables market web navigation webinar calendar webinars weight loss business weight loss data weight loss maintenance weight loss market weight loss medication weight loss therapy weight maintenance weight regain wellness apps * * wet AMD white glove delivery whole-virus wild-type wind-down operations wireless workflow automation workforce workforce termination workplace toxicity world 's z-rostudirsen zasocitinib zelenectide zelicapavir zenocutuzumab zetomipzomib ziclumeran zidesamtinib zocilurtatug pelitecan zoliflodacin zolucatetide zongertinib zopapogene imadenovec-drba zorpocabtagene-autoleucel ( zovegalisib zumilokibart Élancé

Show more Show less

Powered by Blogger

X-Data LLC